US7404950B2
(en)
|
2003-02-18 |
2008-07-29 |
Baylor College Of Medicine |
Induced activation in dendritic cell
|
US20130266551A1
(en)
*
|
2003-11-05 |
2013-10-10 |
St. Jude Children's Research Hospital, Inc. |
Chimeric receptors with 4-1bb stimulatory signaling domain
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
US8129184B2
(en)
|
2006-09-26 |
2012-03-06 |
Cedars-Sinai Medical Center |
Cancer stem cell antigen vaccines and methods
|
US8097256B2
(en)
|
2006-09-28 |
2012-01-17 |
Cedars-Sinai Medical Center |
Cancer vaccines and vaccination methods
|
DK2279253T3
(en)
|
2008-04-09 |
2017-02-13 |
Maxcyte Inc |
Construction and application of therapeutic compositions of freshly isolated cells
|
US9068020B2
(en)
|
2008-09-02 |
2015-06-30 |
Cedars-Sinai Medical Center |
CD133 epitopes
|
US8415150B2
(en)
*
|
2009-02-24 |
2013-04-09 |
The Trustees Of The University Of Pennsylvania |
Methods for treating progressive multifocal leukoencephalopathy (PML)
|
US10426740B1
(en)
|
2010-08-18 |
2019-10-01 |
Avm Biotechnology, Llc |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
EP2630158B1
(en)
|
2010-10-22 |
2018-12-12 |
Dana-Farber Cancer Institute, Inc. |
Discovery of regulatory t cells programmed to suppress an immune response
|
ES2700966T3
(en)
*
|
2010-12-09 |
2019-02-20 |
Univ Pennsylvania |
Use of modified T lymphocytes with chimeric antigen receptors to treat cancer
|
CN103748236B
(en)
|
2011-04-15 |
2018-12-25 |
约翰·霍普金斯大学 |
Safe sequencing system
|
AU2012325915A1
(en)
*
|
2011-10-20 |
2014-04-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD22 chimeric antigen receptors
|
WO2013063419A2
(en)
*
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
IN2014DN06522A
(en)
|
2012-02-22 |
2015-06-12 |
Univ Pennsylvania |
|
BR112014020499A2
(en)
|
2012-02-22 |
2019-09-24 |
Univ Pennsylvania |
isolated nucleic acid sequence, t-cell, vector, and persistent t-cell population
|
PE20190658A1
(en)
|
2012-02-24 |
2019-05-08 |
Abbvie Stemcentrx Llc |
NEW MODULATORS AND EMPLOYMENT METHODS
|
US9359447B2
(en)
|
2012-03-23 |
2016-06-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
RU2766608C2
(en)
|
2012-04-11 |
2022-03-15 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Chimeric antigen receptors targeted b-cell maturation antigen
|
EP3276000A3
(en)
|
2012-05-25 |
2018-02-21 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
MX370495B
(en)
*
|
2012-07-13 |
2019-12-13 |
Univ Pennsylvania |
Methods of assessing the suitability of transduced t cells for administration.
|
EA034644B1
(en)
*
|
2012-07-13 |
2020-03-02 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Use of cart19 to deplete normal b cells to induce tolerance
|
US20160235787A1
(en)
*
|
2012-07-13 |
2016-08-18 |
The Trustees Of The University Of Pennsylvania |
Epitope Spreading Associated with CAR T-Cells
|
HUE061555T2
(en)
|
2012-07-13 |
2023-07-28 |
Univ Pennsylvania |
Toxicity management for anti-tumor activity of cars
|
EA201590207A1
(en)
*
|
2012-07-13 |
2015-05-29 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
COMPOSITIONS AND METHODS OF REGULATION OF CAR-T CELLS
|
SG11201408787PA
(en)
|
2012-07-13 |
2015-01-29 |
Univ Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
SI2884999T1
(en)
*
|
2012-08-20 |
2021-05-31 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
AU2013312838B2
(en)
*
|
2012-09-04 |
2018-11-29 |
Cellectis |
Multi-chain chimeric antigen receptor and uses thereof
|
US9416190B2
(en)
*
|
2012-09-27 |
2016-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
WO2014052545A2
(en)
|
2012-09-28 |
2014-04-03 |
Dana-Farber Cancer Institute, Inc. |
Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
|
WO2014055442A2
(en)
*
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
US9598489B2
(en)
|
2012-10-05 |
2017-03-21 |
The Trustees Of The Univeristy Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
CN110229834B
(en)
*
|
2012-10-24 |
2022-11-01 |
美国卫生和人力服务部 |
M971 chimeric antigen receptor
|
PL2912468T3
(en)
|
2012-10-29 |
2019-04-30 |
Univ Johns Hopkins |
Papanicolaou test for ovarian and endometrial cancers
|
AU2013204922B2
(en)
*
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
AU2015210373B2
(en)
*
|
2012-12-20 |
2017-04-06 |
Celgene Corporation |
Chimeric antigen receptors
|
WO2014124143A1
(en)
*
|
2013-02-06 |
2014-08-14 |
Anthrogenesis Corporation |
Modified t lymphocytes having improved specificity
|
WO2014127296A1
(en)
*
|
2013-02-14 |
2014-08-21 |
Immunocellular Therapeutics, Ltd |
Cancer vaccines and vaccination methods
|
DK3300745T3
(en)
*
|
2013-02-15 |
2019-11-04 |
Univ California |
CHEMICAL ANTIGEN RECEPTOR AND METHODS FOR USING IT
|
ES2814962T3
(en)
|
2013-02-20 |
2021-03-29 |
Novartis Ag |
Efficient targeting of primary human leukemia using anti-CD123 chimeric antigen receptor modified T cells
|
WO2014130657A1
(en)
|
2013-02-20 |
2014-08-28 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
HUE043851T2
(en)
|
2013-02-22 |
2019-09-30 |
Abbvie Stemcentrx Llc |
Antidll3-antibody-pbd conjugates and uses thereof
|
LT2961831T
(en)
|
2013-02-26 |
2020-11-10 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for immunotherapy
|
CA2904230A1
(en)
*
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Engager cells for immunotherapy
|
WO2014153114A1
(en)
*
|
2013-03-14 |
2014-09-25 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
US9944690B2
(en)
|
2013-03-14 |
2018-04-17 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling T cell proliferation
|
US9499855B2
(en)
*
|
2013-03-14 |
2016-11-22 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
US9587237B2
(en)
|
2013-03-14 |
2017-03-07 |
Elwha Llc |
Compositions, methods, and computer systems related to making and administering modified T cells
|
CN105247042B
(en)
|
2013-03-15 |
2021-06-11 |
普林斯顿大学理事会 |
Method and apparatus for high throughput purification
|
CN110186835B
(en)
|
2013-03-15 |
2022-05-31 |
Gpb科学有限公司 |
On-chip microfluidic processing of particles
|
KR102466666B1
(en)
|
2013-03-15 |
2022-11-15 |
메모리얼 슬로안 케터링 캔서 센터 |
Compositions and methods for immunotherapy
|
US20150064153A1
(en)
|
2013-03-15 |
2015-03-05 |
The Trustees Of Princeton University |
High efficiency microfluidic purification of stem cells to improve transplants
|
US9657105B2
(en)
*
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
EP2970372B1
(en)
|
2013-03-15 |
2020-09-30 |
Celgene Corporation |
Modified t lymphocytes
|
ES2769574T3
(en)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
TWI654206B
(en)
*
|
2013-03-16 |
2019-03-21 |
諾華公司 |
Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
MX370173B
(en)
*
|
2013-05-03 |
2019-12-04 |
Ohio State Innovation Foundation |
Cs1-specific chimeric antigen receptor engineered immune effector cells.
|
US10260038B2
(en)
|
2013-05-10 |
2019-04-16 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
US11311575B2
(en)
*
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
EA036200B1
(en)
*
|
2013-05-13 |
2020-10-14 |
Селлектис |
Cd19 specific chimeric antigen receptor and uses thereof
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
JP6463577B2
(en)
|
2013-05-14 |
2019-02-06 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
Human application of modified chimeric antigen receptor (CAR) T cells
|
US9701758B2
(en)
|
2013-05-24 |
2017-07-11 |
Board Of Regents, The University Of Texas System |
Anti-CD19 scFv (FMC63) polypeptide
|
EP3892293A1
(en)
|
2013-06-10 |
2021-10-13 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for reducing immunosupression by tumor cells
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
SG11201601424PA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Site-specific antibody conjugation methods and compositions
|
CN105722522B
(en)
|
2013-08-30 |
2021-10-19 |
得克萨斯大学体系董事会 |
Administration of kynurenine depleting enzymes for tumor therapy
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
ES2764833T3
(en)
|
2013-10-11 |
2020-06-04 |
The United States Of America Represented By The Sec Dep Of Health And Human Services |
TEM8 antibodies and their use
|
KR102339240B1
(en)
|
2013-10-15 |
2021-12-15 |
더 스크립스 리서치 인스티튜트 |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
KR102357968B1
(en)
*
|
2013-10-15 |
2022-02-03 |
더 스크립스 리서치 인스티튜트 |
Chimeric antigen receptor t cell switches and uses thereof
|
CN105683214B
(en)
*
|
2013-10-17 |
2021-03-09 |
新加坡国立大学 |
Chimeric receptors that trigger antibody-dependent cellular cytotoxicity against multiple tumors
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
CN104561069A
(en)
*
|
2013-10-23 |
2015-04-29 |
深圳先进技术研究院 |
Micro-annullus DNA recombinant plasmid containing recombinant chimeric antigen receptor gene expression box, micro-annullus DNA containing expression box and application
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
EA201690987A1
(en)
|
2013-11-13 |
2016-10-31 |
Новартис Аг |
LOW-DOSE IMMUNE MULTIBIDATION MTOR INHIBITORS AND THEIR APPLICATIONS
|
US10246505B2
(en)
|
2013-11-25 |
2019-04-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors to control HIV infection
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
CA2932424C
(en)
|
2013-12-06 |
2023-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
EP3083691A2
(en)
*
|
2013-12-20 |
2016-10-26 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
HUE052573T2
(en)
|
2013-12-20 |
2021-05-28 |
Hutchinson Fred Cancer Res |
Tagged chimeric effector molecules and receptors thereof
|
JP7060324B2
(en)
|
2013-12-20 |
2022-04-26 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Combination therapy with neoantigen vaccine
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
CN107074957B
(en)
*
|
2014-01-13 |
2021-05-07 |
希望之城公司 |
Chimeric Antigen Receptors (CARs) having mutations in the Fc spacer region and methods of use thereof
|
EP3097117B1
(en)
*
|
2014-01-21 |
2023-10-04 |
Novartis Ag |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
JOP20200094A1
(en)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-1 and uses thereof
|
JOP20200096A1
(en)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
Antibody molecules to tim-3 and uses thereof
|
ES2792849T3
(en)
|
2014-02-10 |
2020-11-12 |
Univ Emory |
Expression of chemical polypeptide with variable lymphocyte receptors in immune cells and uses to treat cancer
|
CA2939093A1
(en)
|
2014-02-14 |
2015-08-20 |
Immune Design Corp. |
Immunotherapy of cancer through combination of local and systemic immune stimulation
|
MX369513B
(en)
*
|
2014-02-14 |
2019-11-11 |
Univ Texas |
Chimeric antigen receptors and methods of making.
|
JP6772063B2
(en)
*
|
2014-02-14 |
2020-10-21 |
ベリカム ファーマシューティカルズ, インコーポレイテッド |
Methods for activating cells using inducible chimeric polypeptides
|
PT3105317T
(en)
*
|
2014-02-14 |
2019-02-27 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
CA2939711C
(en)
|
2014-02-21 |
2020-09-29 |
Cellectis |
Method for in situ inhibition of regulatory t cells
|
JP2017514143A
(en)
|
2014-02-21 |
2017-06-01 |
アッヴィ・ステムセントルクス・エル・エル・シー |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
CN106279434B
(en)
*
|
2014-02-24 |
2020-07-03 |
西比曼生物科技(上海)有限公司 |
Engineered CD20 targeted NKT cell and preparation method and application thereof
|
AU2015222917A1
(en)
|
2014-02-27 |
2016-09-15 |
Lycera Corporation |
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
|
CN104877028A
(en)
*
|
2014-02-28 |
2015-09-02 |
百奥迈科生物技术有限公司 |
Anti-DOTA chimeric antigen receptor-modified T cells and anti-tumor applications thereof
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
KR102235201B1
(en)
*
|
2014-03-05 |
2021-04-05 |
유씨엘 비즈니스 리미티드 |
Chimeric antigen receptor(car) with antigen binding domains to the t cell receptor beta constant region
|
US20230027993A1
(en)
|
2014-03-05 |
2023-01-26 |
Autolus Limited |
Methods
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
CA2943008C
(en)
*
|
2014-03-19 |
2021-03-30 |
Cellectis |
Cd123 specific chimeric antigen receptors for cancer immunotherapy
|
WO2015143224A1
(en)
*
|
2014-03-19 |
2015-09-24 |
Ambrx, Inc. |
Chimeric antigen receptor-modified t-cells
|
IL295906A
(en)
|
2014-03-21 |
2022-10-01 |
Abbvie Inc |
Anti-egfr antibodies and antibody drug conjugates
|
MX370788B
(en)
|
2014-04-03 |
2020-01-06 |
Cellectis |
Cd33 specific chimeric antigen receptors for cancer immunotherapy.
|
CA2940671A1
(en)
*
|
2014-04-07 |
2015-10-15 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
SG11201608389RA
(en)
|
2014-04-07 |
2016-11-29 |
Minerva Biotechnologies Corp |
Anti-nme antibody
|
MY192522A
(en)
|
2014-04-10 |
2022-08-25 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Defined composition gene modified t-cell products
|
AU2015248956B2
(en)
|
2014-04-14 |
2020-06-25 |
Cellectis |
BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
|
BR112016024579A2
(en)
|
2014-04-23 |
2017-10-10 |
Juno Therapeutics Inc |
Methods for Isolation, Culture, and Genetic Engineering of Immune Cell Populations for Foster Therapy
|
EP3134434A4
(en)
*
|
2014-04-25 |
2017-10-25 |
Bluebird Bio, Inc. |
Kappa/lambda chimeric antigen receptors
|
DK3689899T3
(en)
|
2014-04-25 |
2021-11-22 |
2Seventy Bio Inc |
CHIMARY MND PROMOTER ANTIGEN RECEPTORS
|
EP3134095B1
(en)
|
2014-04-25 |
2020-04-22 |
Bluebird Bio, Inc. |
Improved methods for manufacturing adoptive cell therapies
|
US10494422B2
(en)
*
|
2014-04-29 |
2019-12-03 |
Seattle Children's Hospital |
CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies
|
GB201407852D0
(en)
|
2014-05-02 |
2014-06-18 |
Iontas Ltd |
Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
|
DK3166968T3
(en)
*
|
2014-05-02 |
2021-12-06 |
Univ Pennsylvania |
Compositions and Methods for Chimeric Autoantibody Receptor T Cells
|
US10167330B2
(en)
|
2014-05-02 |
2019-01-01 |
Emory University |
Modified recombinant variable lymphocyte receptors (VLR)
|
EP3140291A4
(en)
|
2014-05-05 |
2018-01-10 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
US10189777B2
(en)
|
2014-05-05 |
2019-01-29 |
Lycera Corporation |
Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease
|
US10604740B2
(en)
|
2014-05-14 |
2020-03-31 |
Carsgen Therapeutics Limited |
Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein
|
DK3143134T3
(en)
|
2014-05-15 |
2021-01-04 |
Nat Univ Singapore |
Modified, natural killer cells and their uses
|
CN106536564B
(en)
|
2014-06-02 |
2021-08-31 |
美国卫生和人力服务部 |
Chimeric antigen receptor targeting CD-19
|
WO2015188119A1
(en)
|
2014-06-06 |
2015-12-10 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
US20180134795A1
(en)
*
|
2014-06-17 |
2018-05-17 |
Cellectis |
Cd123 specific multi-chain chimeric antigen receptor
|
GB201506423D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
MA40253A
(en)
|
2014-07-15 |
2017-05-24 |
Juno Therapeutics Inc |
Engineered cells for adoptive cell therapy
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
SG11201700476VA
(en)
|
2014-07-21 |
2017-02-27 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
BR112017000939A2
(en)
|
2014-07-21 |
2017-11-14 |
Novartis Ag |
cancer treatment using a cll-1 chimeric antigen receptor
|
AU2015292590B2
(en)
|
2014-07-24 |
2020-01-16 |
2Seventy Bio, Inc. |
BCMA chimeric antigen receptors
|
WO2016016344A1
(en)
*
|
2014-07-29 |
2016-02-04 |
Cellectis |
Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
|
RU2017102769A
(en)
*
|
2014-07-29 |
2018-08-28 |
Пфайзер Инк. |
EGFRvIII SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY
|
WO2016016343A1
(en)
|
2014-07-31 |
2016-02-04 |
Cellectis |
Ror1 specific multi-chain chimeric antigen receptor
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
DK3183268T3
(en)
|
2014-08-19 |
2020-05-11 |
Univ Pennsylvania |
CANCER TREATMENT USING A CD123 CHEMICAL ANTIGEN RECEPTOR
|
US20170269076A1
(en)
|
2014-08-27 |
2017-09-21 |
Dana-Farber Cancer Institute, Inc. |
Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
|
TWI751102B
(en)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
Antibodies and chimeric antigen receptors specific for cd19
|
EP2990416B1
(en)
*
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
WO2016033488A1
(en)
|
2014-08-29 |
2016-03-03 |
Board Of Regents, The University Of Texas System |
Administration of kynurenine depleting enzymes for tumor therapy
|
CA2959168A1
(en)
*
|
2014-09-02 |
2016-03-10 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
|
WO2016034666A1
(en)
|
2014-09-04 |
2016-03-10 |
Cellectis |
Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
AU2015315199B2
(en)
*
|
2014-09-09 |
2020-02-27 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
EP3925622A1
(en)
|
2014-09-13 |
2021-12-22 |
Novartis AG |
Combination therapies
|
CN114621969A
(en)
|
2014-09-17 |
2022-06-14 |
诺华股份有限公司 |
Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
JP6613304B2
(en)
|
2014-09-17 |
2019-12-04 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Anti-CD276 antibody (B7H3)
|
BR112017005631A2
(en)
*
|
2014-09-19 |
2018-06-26 |
City Of Hope |
il13ra2-targeted chimeric costimulator antigen receptor t cells
|
HUE054673T2
(en)
*
|
2014-10-02 |
2021-09-28 |
Wistar Inst |
Methods and compositions for treating cancer
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
KR20170068539A
(en)
*
|
2014-10-07 |
2017-06-19 |
셀렉티스 |
Method for modulating car-induced immune cells activity
|
SG11201702895SA
(en)
|
2014-10-08 |
2017-05-30 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
LT3597742T
(en)
|
2014-10-09 |
2022-09-12 |
Yamaguchi University |
Car expression vector and car-expressing t cells
|
NZ730563A
(en)
|
2014-10-14 |
2019-05-31 |
Halozyme Inc |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
KR20170068598A
(en)
|
2014-10-20 |
2017-06-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Methods and compositions for dosing in adoptive cell therapy
|
US20170335331A1
(en)
*
|
2014-10-31 |
2017-11-23 |
The Trustees Of The University Of Pennsylvania |
Altering Gene Expression in CART Cells and Uses Thereof
|
CA2966035A1
(en)
|
2014-10-31 |
2016-05-06 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of stimulating and expanding t cells
|
US20170363629A1
(en)
*
|
2014-11-05 |
2017-12-21 |
Board Of Regents, The University Of Texas System |
Biomarkers and targets for cancer immunotherapy
|
KR20170075785A
(en)
|
2014-11-05 |
2017-07-03 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
Gene modified immune effector cells and engineered cells for expansion of immune effector cells
|
ES2806126T3
(en)
|
2014-11-05 |
2021-02-16 |
Univ Texas |
Chimeric antigen receptors (CARs) selectively target protein complexes
|
RS60685B1
(en)
|
2014-11-05 |
2020-09-30 |
Juno Therapeutics Inc |
Methods for transduction and cell processing
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
MX2017006167A
(en)
|
2014-11-12 |
2018-03-23 |
Siamab Therapeutics Inc |
Glycan-interacting compounds and methods of use.
|
CN105601746B
(en)
*
|
2014-11-21 |
2021-02-19 |
三生国健药业(上海)股份有限公司 |
Fusion protein of chimeric Fc receptor and preparation method and application thereof
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
MX2017007138A
(en)
*
|
2014-12-03 |
2017-08-28 |
Juno Therapeutics Inc |
Methods and compositions for adoptive cell therapy.
|
IL252617B
(en)
|
2014-12-05 |
2022-09-01 |
Memorial Sloan Kettering Cancer Center |
Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
|
CN118271463A
(en)
|
2014-12-05 |
2024-07-02 |
纪念斯隆-凯特琳癌症中心 |
Chimeric antigen receptor targeting G-protein coupled receptor and use thereof
|
CN107206077B
(en)
|
2014-12-05 |
2021-06-08 |
纪念斯隆-凯特琳癌症中心 |
Antibodies targeting G-protein coupled receptors and methods of use
|
AU2015357533B2
(en)
|
2014-12-05 |
2021-10-07 |
Eureka Therapeutics, Inc. |
Antibodies targeting B-cell maturation antigen and methods of use
|
IL290459B2
(en)
|
2014-12-05 |
2023-11-01 |
Hope City |
Cs1 targeted chimeric antigen receptor-modified t cells
|
CN107207616B
(en)
*
|
2014-12-08 |
2021-11-19 |
美国卫生和人力服务部 |
anti-CD 70 chimeric antigen receptor
|
NZ733025A
(en)
|
2014-12-12 |
2022-01-28 |
2Seventy Bio Inc |
Bcma chimeric antigen receptors
|
EP3230441A4
(en)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
CA3008162A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
CA2971186A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
KR20200003939A
(en)
|
2014-12-24 |
2020-01-10 |
유씨엘 비즈니스 리미티드 |
Cell
|
SG11201705293WA
(en)
|
2014-12-29 |
2017-07-28 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
MA41346A
(en)
|
2015-01-12 |
2017-11-21 |
Juno Therapeutics Inc |
POST-TRANSCRIPTIONAL REGULATORY ELEMENTS OF MODIFIED HEPATITIS
|
EP3245231B1
(en)
|
2015-01-16 |
2020-08-12 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
AU2016212159A1
(en)
|
2015-01-26 |
2017-07-13 |
Cellectis |
Anti-HSP70 specific Chimeric Antigen Receptors (CARs) for cancer immunotherapy
|
ES2789330T3
(en)
*
|
2015-01-29 |
2020-10-26 |
Univ Minnesota |
Chimeric antigen receptors, compositions and methods
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
JP6895380B2
(en)
*
|
2015-02-06 |
2021-06-30 |
ナショナル ユニバーシティ オブ シンガポール |
Methods for Improving the Efficacy of Therapeutic Immune Cells
|
WO2016130516A1
(en)
|
2015-02-09 |
2016-08-18 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
US20160228544A1
(en)
*
|
2015-02-11 |
2016-08-11 |
Ensysce Biosciences, Inc. |
Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related Thereto
|
EP3258967A4
(en)
|
2015-02-20 |
2018-10-03 |
Ohio State Innovation Foundation |
Bivalent antibody directed against nkg2d and tumor associated antigens
|
MA41613A
(en)
*
|
2015-02-23 |
2018-01-02 |
Abbvie Stemcentrx Llc |
ANTI-DLL3 CHEMERICAL ANTIGENIC RECEPTORS AND METHODS FOR USING SUCH RECEIVERS
|
MX2017010721A
(en)
|
2015-02-24 |
2018-08-28 |
Univ California |
Binding-triggered transcriptional switches and methods of use thereof.
|
WO2016138091A2
(en)
|
2015-02-24 |
2016-09-01 |
Board Of Regents, The University Of Texas System |
Selection methods for genetically-modified t cells
|
CA2977106A1
(en)
*
|
2015-02-27 |
2016-09-01 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
CA2976684C
(en)
|
2015-03-02 |
2024-03-05 |
Innovative Cellular Therapeutics CO., LTD. |
Reducing immune tolerance induced by pd-l1
|
US10195272B2
(en)
|
2015-03-02 |
2019-02-05 |
The Nemours Foundation |
Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
|
MY196588A
(en)
*
|
2015-03-05 |
2023-04-19 |
Hutchinson Fred Cancer Res |
Immunomodulatory Fusion Proteins and uses Thereof
|
CN107614062A
(en)
|
2015-03-12 |
2018-01-19 |
加利福尼亚大学董事会 |
With the method for ROR gamma inhibitors treating cancers
|
US10738116B2
(en)
|
2015-03-19 |
2020-08-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
|
SI3271389T1
(en)
|
2015-03-20 |
2020-09-30 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to gp120 and their use
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
US20190119385A1
(en)
*
|
2015-03-27 |
2019-04-25 |
University Of Southern California |
Hla-g as a novel target for car t-cell immunotherapy
|
EP3273994B1
(en)
|
2015-03-27 |
2021-12-01 |
University of Southern California |
Car t-cell therapy directed to lhr for the treatment of solid tumors
|
WO2016161415A2
(en)
*
|
2015-04-02 |
2016-10-06 |
Memorial Sloan Kettering Cancer Center |
Tnfrsf14/ hvem proteins and methods of use thereof
|
RU2754041C2
(en)
|
2015-04-03 |
2021-08-25 |
Еурека Терапьютикс, Инк. |
Structures aimed at afp/mhc peptide complexes and types of their use
|
CN108367057B
(en)
|
2015-04-06 |
2022-11-22 |
赛通免疫股份有限公司 |
EGFR-directed CAR therapy for glioblastoma
|
MX2017012679A
(en)
|
2015-04-06 |
2018-02-09 |
Subdomain Llc |
De novo binding domain containing polypeptides and uses thereof.
|
MX2017012939A
(en)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell.
|
US11091546B2
(en)
|
2015-04-15 |
2021-08-17 |
The Scripps Research Institute |
Optimized PNE-based chimeric receptor T cell switches and uses thereof
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
US20180117155A1
(en)
|
2015-04-25 |
2018-05-03 |
The General Hospital Corporation |
Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer
|
WO2016176651A2
(en)
*
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
EP3288570A4
(en)
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
CA2984180A1
(en)
*
|
2015-04-30 |
2016-11-03 |
University Of Southern California |
Secretory tnt car cell immunotherapy
|
WO2016178996A1
(en)
|
2015-05-01 |
2016-11-10 |
The Regents Of The University Of California |
Glycan-dependent immunotherapeutic molecules
|
EP3292119A4
(en)
|
2015-05-05 |
2018-10-03 |
Lycera Corporation |
DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
|
EP4233546A3
(en)
|
2015-05-06 |
2023-09-27 |
SNIPR Technologies Limited |
Altering microbial populations & modifying microbiota
|
US10968426B2
(en)
|
2015-05-08 |
2021-04-06 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
US20200316231A1
(en)
*
|
2015-05-10 |
2020-10-08 |
The Trustees Of The University Of Pennsylvania |
Compositions And Methods For Imaging Immune Cells
|
US11253616B2
(en)
|
2017-09-06 |
2022-02-22 |
The Trustees Of The University Of Pennsylvania |
Small molecules for dual function positron emission tomography (PET) and cell suicide switches
|
WO2016180467A1
(en)
*
|
2015-05-11 |
2016-11-17 |
Biontech Cell & Gene Therapies Gmbh |
Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
|
WO2016187068A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
WO2016187216A1
(en)
*
|
2015-05-18 |
2016-11-24 |
Bluebird Bio, Inc. |
Anti-ror1 chimeric antigen receptors
|
EP3466967A1
(en)
|
2015-05-18 |
2019-04-10 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US10434153B1
(en)
|
2015-05-20 |
2019-10-08 |
Kim Leslie O'Neill |
Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
|
CR20200476A
(en)
|
2015-05-20 |
2020-12-02 |
Dana Farber Cancer Inst Inc |
Shared neoantigens
|
TW201706300A
(en)
|
2015-05-20 |
2017-02-16 |
瑟勒提斯公司 |
Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
|
US10576076B2
(en)
|
2015-05-20 |
2020-03-03 |
Novartis Ag |
Pharmaceutical combination of everolimus with dactolisib
|
CN107847583A
(en)
*
|
2015-05-28 |
2018-03-27 |
阿尔莫生物科技股份有限公司 |
PEGylated Interleukin 10 for treating cancer
|
CN114452395A
(en)
|
2015-05-28 |
2022-05-10 |
凯德药业股份有限公司 |
Diagnostic methods for T cell therapy
|
IL312426A
(en)
*
|
2015-05-28 |
2024-06-01 |
Kite Pharma Inc |
Methods of conditioning patients for t cell therapy
|
JP6949728B2
(en)
|
2015-05-29 |
2021-10-13 |
ジュノー セラピューティクス インコーポレイテッド |
Compositions and Methods for Modulating Inhibitory Interactions in Genetically Engineered Cells
|
EP3303381A1
(en)
|
2015-05-29 |
2018-04-11 |
Fred Hutchinson Cancer Research Center |
Compositions for cellular immunotherapy
|
MX2017015493A
(en)
|
2015-05-30 |
2018-02-09 |
Molecular Templates Inc |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same.
|
AU2016270474A1
(en)
*
|
2015-06-04 |
2018-01-04 |
University Of Southern California |
Lym-1 and Lym-2 targeted CAR cell immunotherapy
|
WO2016196957A1
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Flow-through paramagnetic particle-based cell separation and paramagnetic particle removal
|
EP3307319A4
(en)
|
2015-06-09 |
2019-05-22 |
Memorial Sloan Kettering Cancer Center |
T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
|
CN113502270B
(en)
|
2015-06-10 |
2024-06-18 |
南克维斯特公司 |
Modified NK-92 cells for the treatment of cancer
|
MX2017016134A
(en)
|
2015-06-11 |
2018-08-15 |
Lycera Corp |
Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease.
|
CA2983456A1
(en)
*
|
2015-06-12 |
2016-12-15 |
Immunomedics, Inc. |
Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
|
CN105177031B
(en)
*
|
2015-06-12 |
2018-04-24 |
北京艺妙神州医疗科技有限公司 |
T cell of Chimeric antigen receptor modification and application thereof
|
CA2989347A1
(en)
|
2015-06-12 |
2016-12-15 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered t-cells
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
PL3310805T3
(en)
|
2015-06-19 |
2021-08-23 |
Sebastian KOBOLD |
Pd-1-cd28 fusion proteins and their use in medicine
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
JP6961497B2
(en)
|
2015-06-25 |
2021-11-05 |
アイセル・ジーン・セラピューティクス・エルエルシー |
Composition of chimeric antibody receptors (CARs) and how to use them
|
US11059880B2
(en)
|
2015-06-30 |
2021-07-13 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
|
MA42902A
(en)
*
|
2015-07-08 |
2018-05-16 |
Univ Johns Hopkins |
MARINAL-INFILTRATING LYMPHOCYTES (MIL) AS A SOURCE OF T-LYMPHOCYTES FOR CHEMERIC ANTIGEN RECEPTOR (CAR) THERAPY
|
WO2017011316A1
(en)
*
|
2015-07-10 |
2017-01-19 |
The Trustees Of The University Of Pennsylvania |
Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor
|
MA42895A
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
EP3325504A1
(en)
|
2015-07-21 |
2018-05-30 |
Novartis AG |
Methods for improving the efficacy and expansion of immune cells
|
US10493139B2
(en)
|
2015-07-24 |
2019-12-03 |
Innovative Cellular Therapeutics CO., LTD. |
Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
|
CA2992742A1
(en)
|
2015-07-28 |
2017-02-02 |
The Trustees Of The University Of Pennsylvania |
Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
|
WO2017023803A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
MX2018001502A
(en)
*
|
2015-08-05 |
2018-08-01 |
Yoo Young Pharm Co Ltd |
Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed.
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
CN108174604B
(en)
|
2015-08-07 |
2023-06-23 |
西雅图儿童医院(Dba西雅图儿童研究所) |
Bispecific CAR T cells for solid tumor targeting
|
US11286531B2
(en)
|
2015-08-11 |
2022-03-29 |
The Johns Hopkins University |
Assaying ovarian cyst fluid
|
US11352439B2
(en)
|
2015-08-13 |
2022-06-07 |
Kim Leslie O'Neill |
Macrophage CAR (MOTO-CAR) in immunotherapy
|
CN106467906B
(en)
*
|
2015-08-20 |
2019-09-27 |
北京马力喏生物科技有限公司 |
Construct, transgenosis lymphocyte and its preparation method and application
|
US10976232B2
(en)
|
2015-08-24 |
2021-04-13 |
Gpb Scientific, Inc. |
Methods and devices for multi-step cell purification and concentration
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
CN108135932A
(en)
*
|
2015-08-28 |
2018-06-08 |
宾夕法尼亚大学董事会 |
Express the method and composition of the cell of signal transduction molecule in chimeric cell
|
EP3340998B1
(en)
*
|
2015-08-28 |
2023-01-11 |
The Trustees of the University of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
CA2996893A1
(en)
|
2015-08-31 |
2017-03-09 |
Bluebird Bio, Inc. |
Anti-sialyl tn chimeric antigen receptors
|
CN108780084B
(en)
|
2015-09-03 |
2022-07-22 |
诺华股份有限公司 |
Biomarkers predictive of cytokine release syndrome
|
KR20180043841A
(en)
*
|
2015-09-11 |
2018-04-30 |
카리나 바이오테크 피티와이 엘티디 |
Chimeric antigen receptors and uses thereof
|
MA44909A
(en)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
THERAPEUTIC ASSOCIATION OF A CD19 INHIBITOR AND A BTK INHIBITOR
|
AU2016324303A1
(en)
*
|
2015-09-18 |
2018-04-26 |
The General Hospital Corporation Dba Massachusetts General Hospital |
Modified T-cells having anti-fugetactic properties and uses thereof
|
WO2017049208A1
(en)
|
2015-09-18 |
2017-03-23 |
The General Hospital Corporation Dba Massachusetts General Hospital |
Localized delivery of anti-fugetactic agent for treatment of cancer
|
CN108779161A
(en)
*
|
2015-09-22 |
2018-11-09 |
宾夕法尼亚大学董事会 |
Redirect method of the T cell to treat HIV infection
|
JP6955487B2
(en)
|
2015-09-24 |
2021-10-27 |
アブビトロ, エルエルシー |
HIV antibody composition and usage
|
AU2016326734B2
(en)
|
2015-09-25 |
2022-07-07 |
Abvitro Llc |
High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences
|
WO2017058752A1
(en)
*
|
2015-09-28 |
2017-04-06 |
Trustees Of Dartmouth College |
Chimeric antigen receptor anti-inflammatory cells and methods of use
|
EP3355937A4
(en)
|
2015-09-28 |
2019-04-17 |
Regents of the University of Minnesota |
Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity
|
ES2809550T3
(en)
*
|
2015-10-06 |
2021-03-04 |
Hope City |
Chimeric antigen receptors directed against PSCA
|
AU2016335750B2
(en)
|
2015-10-07 |
2023-05-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
EP3359650A4
(en)
|
2015-10-08 |
2019-03-20 |
Innovative Cellular Therapeutics Co., Ltd. |
Activation and expansion of t cells
|
US11517590B2
(en)
*
|
2015-10-08 |
2022-12-06 |
National University Corporation Tokai National Higher Education And Research System |
Method for preparing genetically-modified T cells which express chimeric antigen receptor
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017062867A1
(en)
*
|
2015-10-09 |
2017-04-13 |
Helmy Eltoukhy |
Population based treatment recommender using cell free dna
|
CN105153315B
(en)
*
|
2015-10-09 |
2019-04-02 |
重庆精准生物技术有限公司 |
Immunosupress receptor combination tumor antigen Chimerical receptor and its application
|
CN108779162B
(en)
|
2015-10-09 |
2021-12-07 |
美天施生物科技有限公司 |
Chimeric antigen receptors and methods of use
|
CN105924530B
(en)
*
|
2015-10-13 |
2019-08-06 |
中国人民解放军总医院 |
Chimeric antigen receptor and its gene and recombinant expression carrier, CAR20-NKT cell and its preparation method and application
|
CN106755023A
(en)
*
|
2015-10-15 |
2017-05-31 |
中国人民解放军军事医学科学院附属医院 |
Chimeric antigen receptor immunocyte with safety switch and preparation method and application
|
IL300420B1
(en)
|
2015-10-16 |
2024-05-01 |
Univ Columbia |
Compositions and methods for inhibition of lineage specific antigens
|
ES2895901T3
(en)
|
2015-10-16 |
2022-02-23 |
Univ Muenchen Ludwig Maximilians |
CXCR6-transduced T cells for targeted tumor therapy
|
AU2016341131A1
(en)
|
2015-10-19 |
2018-05-10 |
University Of Massachusetts |
Anti-cancer and anti-inflammatory therapeutics and methods thereof
|
CN108366995A
(en)
|
2015-10-20 |
2018-08-03 |
凯德药业股份有限公司 |
The method for preparing the T cell for T cell therapy
|
WO2017068419A2
(en)
|
2015-10-22 |
2017-04-27 |
Juno Therapeutics Gmbh |
Methods, kits, agents and apparatuses for transduction
|
MA45489A
(en)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
CELL CULTURE PROCESSES, ASSOCIATED KITS AND APPARATUS
|
MA45488A
(en)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
CELL CULTURE PROCESSES, KITS AND APPARATUS
|
CN105132445B
(en)
*
|
2015-10-23 |
2018-10-02 |
马健颖 |
A kind of receptor protein of specially recognizing tumor cells, T lymphocytes and NK cells
|
KR20180091820A
(en)
*
|
2015-10-23 |
2018-08-16 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Programmable universal cellular receptors and methods for their use
|
US11059879B2
(en)
|
2015-10-27 |
2021-07-13 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
WO2017079703A1
(en)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
MA44314A
(en)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
CHEMERICAL RECEPTORS CONTAINING TRAF-INDUCING DOMAINS, AND ASSOCIATED COMPOSITIONS AND METHODS
|
MX2018005061A
(en)
|
2015-11-12 |
2019-02-28 |
Siamab Therapeutics Inc |
Glycan-interacting compounds and methods of use.
|
CN105331585A
(en)
*
|
2015-11-13 |
2016-02-17 |
科济生物医药(上海)有限公司 |
Chimeric antigen receptor-modified immunologic effector cell with PD-L1 blocking agent
|
CN105384826A
(en)
*
|
2015-11-19 |
2016-03-09 |
广州熙帝生物科技有限公司 |
Cord blood nucleated cell for expressing chimeric antigen receptor and application of cord blood nucleated cell
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
CN109152824B
(en)
*
|
2015-11-27 |
2022-12-06 |
卡瑟里克斯私人有限公司 |
Genetically modified cells and uses thereof
|
CA3007262A1
(en)
|
2015-12-03 |
2017-06-08 |
Lucas James Thompson |
Modified chimeric receptors and related compositions and methods
|
US20200297760A1
(en)
|
2015-12-03 |
2020-09-24 |
Juno Therapeutics, Inc. |
Compositions and methods for reducing immune responses against chimeric antigen receptors
|
CN108699557A
(en)
|
2015-12-04 |
2018-10-23 |
诺华股份有限公司 |
Composition for oncology to be immunized and method
|
EP3384013A4
(en)
*
|
2015-12-04 |
2019-07-10 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Antigen-specific t cells for inducing immune tolerance
|
ES2901795T3
(en)
|
2015-12-04 |
2022-03-23 |
Juno Therapeutics Inc |
Methods and compositions related to toxicity associated with cell therapy
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
US10953003B2
(en)
|
2015-12-14 |
2021-03-23 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
CA3008279A1
(en)
|
2015-12-14 |
2017-06-22 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
EP3393504A1
(en)
|
2015-12-22 |
2018-10-31 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
SI3393468T1
(en)
|
2015-12-22 |
2023-01-31 |
X4 Pharmaceuticals, Inc. |
Methods for treating immunodeficiency disease
|
BR112018013074A2
(en)
|
2015-12-30 |
2018-12-11 |
Novartis Ag |
immune effector cell therapies with enhanced efficacy
|
GB201600328D0
(en)
|
2016-01-08 |
2016-02-24 |
Univ Oslo Hf |
Anti-CD37 chimeric antigen receptors and immune cells expressing them
|
BR112018013914A2
(en)
|
2016-01-08 |
2018-12-11 |
Univ California |
conditionally active heterodimeric polypeptides and methods of using this
|
CN105950645A
(en)
*
|
2016-01-11 |
2016-09-21 |
灏灵赛奥(天津)生物科技有限公司 |
Humanized fusion gene segment of CAR-CD19 antigen receptor, construction method and application thereof
|
US11505599B2
(en)
|
2016-01-14 |
2022-11-22 |
Memorial Sloan-Kettering Cancer Center |
T cell receptor-like antibodies specific for Foxp3-derived peptides
|
JP2019504071A
(en)
|
2016-01-15 |
2019-02-14 |
ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー |
Methods and compositions for treating cancer
|
BR112018014585A2
(en)
|
2016-01-21 |
2018-12-11 |
Pfizer |
chimeric antigen receptors that direct variant epidermal growth factor receptor iii
|
US10221242B2
(en)
|
2016-01-21 |
2019-03-05 |
Pfizer Inc. |
Antibodies specific for epidermal growth factor receptor variant III and their uses
|
CN105567640A
(en)
*
|
2016-01-27 |
2016-05-11 |
苏州佰通生物科技有限公司 |
Chimeric antigen receptor adipose-derived stem cell and preparation method thereof
|
US10179919B2
(en)
|
2016-02-23 |
2019-01-15 |
Immune Design Corp. |
Multigenome retroviral vector preparations and methods and systems for producing and using same
|
EP3423483A4
(en)
|
2016-03-02 |
2019-08-21 |
Board Of Regents Of the University Of Texas System |
Human kynureninase enzyme variants having improved pharmacological properties
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
CA3017603A1
(en)
*
|
2016-03-14 |
2017-09-21 |
Wisconsin Alumni Research Foundation |
Methods of t cell expansion and activation
|
WO2017161208A1
(en)
|
2016-03-16 |
2017-09-21 |
Juno Therapeutics, Inc. |
Methods for determining dosing of a therapeutic agent and related treatments
|
MA43759A
(en)
|
2016-03-16 |
2018-11-28 |
Jason Connor |
PROCESSES FOR THE ADAPTIVE DESIGN OF A TREATMENT REGIME AND ASSOCIATED TREATMENTS
|
RU2770812C2
(en)
|
2016-03-17 |
2022-04-22 |
Ямагути Университи |
Immunocompetent cell and expression vector expressing regulatory factors of immune function
|
EP3430038B1
(en)
|
2016-03-18 |
2021-06-16 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for cd20 immunotherapy
|
WO2017165571A1
(en)
|
2016-03-22 |
2017-09-28 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
KR20230165383A
(en)
|
2016-04-01 |
2023-12-05 |
카이트 파마 인코포레이티드 |
Chimeric receptors and methods of use thereof
|
WO2017167217A1
(en)
*
|
2016-04-01 |
2017-10-05 |
Innovative Cellular Therapeutics CO., LTD. |
Use of chimeric antigen receptor modified cells to treat cancer
|
MY201207A
(en)
|
2016-04-01 |
2024-02-09 |
Amgen Inc |
Chimeric receptors to flt3 and methods of use thereof
|
CA3019135A1
(en)
|
2016-04-01 |
2017-10-05 |
Kite Pharma, Inc. |
Bcma binding molecules and methods of use thereof
|
JP7034934B2
(en)
|
2016-04-01 |
2022-03-14 |
カイト ファーマ インコーポレイテッド |
Chimeric antigen and T cell receptor, and how to use
|
US10654934B2
(en)
|
2016-04-01 |
2020-05-19 |
Innovative Cellular Therapeutics CO., LTD. |
Use of chimeric antigen receptor modified cells to treat cancer
|
ES2957890T3
(en)
|
2016-04-08 |
2024-01-29 |
Univ Emory |
Methods for treating cancer and infectious diseases using cell therapies
|
US11337969B2
(en)
|
2016-04-08 |
2022-05-24 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
EP3443001A4
(en)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
CN106399255B
(en)
*
|
2016-04-13 |
2019-10-18 |
阿思科力(苏州)生物科技有限公司 |
PD-1 CAR-T cell and its preparation method and application
|
US10188749B2
(en)
|
2016-04-14 |
2019-01-29 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
SG11201809041TA
(en)
|
2016-04-15 |
2018-11-29 |
Novartis Ag |
Compositions and methods for selective protein expression
|
KR20190006495A
(en)
|
2016-04-15 |
2019-01-18 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
CD80 variant immunoregulatory proteins and uses thereof
|
CN105907719B
(en)
*
|
2016-04-18 |
2019-10-18 |
阿思科力(苏州)生物科技有限公司 |
Anti ROBO1 CAR-T cell and its preparation and application
|
US20190346442A1
(en)
|
2016-04-18 |
2019-11-14 |
The Broad Institute, Inc. |
Improved hla epitope prediction
|
CN109414512A
(en)
*
|
2016-04-22 |
2019-03-01 |
科济生物医药(上海)有限公司 |
Composition and method for cellular immunotherapy
|
WO2017192536A1
(en)
|
2016-05-02 |
2017-11-09 |
University Of Kansas |
Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
|
CN116850305A
(en)
|
2016-05-06 |
2023-10-10 |
朱诺治疗学股份有限公司 |
Genetically engineered cells and methods of making same
|
US11261223B2
(en)
*
|
2016-05-11 |
2022-03-01 |
The University Of Chicago |
Methods of treating cancers with CT45 targeted therapies
|
CN117431234A
(en)
|
2016-05-27 |
2024-01-23 |
阿迪根有限公司 |
Peptides and nanoparticles for intracellular delivery of genome editing molecules
|
CA3025516A1
(en)
*
|
2016-05-27 |
2017-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Flt3-specific chimeric antigen receptors and methods using same
|
CN105837693A
(en)
*
|
2016-05-30 |
2016-08-10 |
李斯文 |
BCMA-based (B cell maturation antigen-based) chimeric antigen receptor and preparation method and application thereof
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
JP2019517518A
(en)
|
2016-06-03 |
2019-06-24 |
メモリアル スローン ケタリング キャンサー センター |
Adoptive cell therapy as an early treatment option
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
MA45341A
(en)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
METHODS FOR TREATING B-LYMPHOCYTE MALIGNITIES USING ADOPTIVE CELL THERAPY
|
WO2017213979A1
(en)
*
|
2016-06-06 |
2017-12-14 |
St. Jude Children's Research Hospital |
Anti-cd7 chimeric antigen receptor and method of use thereof
|
EP3469000A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
WO2017214458A2
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
JP2019526529A
(en)
|
2016-06-08 |
2019-09-19 |
アッヴィ・インコーポレイテッド |
Anti-B7-H3 antibody and antibody drug conjugate
|
EP3468598A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
US11787848B2
(en)
|
2016-06-08 |
2023-10-17 |
Precigen, Inc. |
CD33 specific chimeric antigen receptors
|
WO2017214462A2
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
TWI762487B
(en)
|
2016-06-08 |
2022-05-01 |
美商艾伯維有限公司 |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CN107523545A
(en)
*
|
2016-06-20 |
2017-12-29 |
上海细胞治疗研究院 |
A kind of lethal cell of high efficiency stable expression antibody and application thereof
|
US11332470B2
(en)
|
2016-06-21 |
2022-05-17 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
EP3808748A1
(en)
|
2016-06-21 |
2021-04-21 |
X4 Pharmaceuticals, Inc. |
Substituted piperidines as cxcr4-inhibitors
|
JP7084624B2
(en)
|
2016-06-21 |
2022-06-15 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
CXCR4 inhibitor and its use
|
CN106117367B
(en)
*
|
2016-06-24 |
2020-02-11 |
安徽未名细胞治疗有限公司 |
HER-3 specific chimeric antigen receptor and application thereof
|
JP7114490B2
(en)
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
Construction of chimeric antibody receptors (CARs) and methods of their use
|
MA45491A
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
|
EP3475446A1
(en)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
MX2018015414A
(en)
|
2016-06-30 |
2019-08-01 |
Hoffmann La Roche |
Improved adoptive t-cell therapy.
|
ES2960835T3
(en)
|
2016-07-12 |
2024-03-06 |
Kite Pharma Inc |
Antigen binding molecules and methods of use thereof
|
JP2018035137A
(en)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
Novel anti-fibroblast activated protein (FAP) binding agent and use thereof
|
JP7219376B2
(en)
|
2016-07-15 |
2023-02-08 |
ノバルティス アーゲー |
Treatment and prevention of cytokine release syndrome using chimeric antigen receptors in combination with kinase inhibitors
|
US11242386B2
(en)
*
|
2016-07-18 |
2022-02-08 |
Helix Biopharma Corp. |
CEACAM6 CAR immune cells to treat cancers
|
CN109641947B
(en)
|
2016-07-20 |
2023-04-14 |
犹他大学研究基金会 |
CD229CAR T cells and methods of use thereof
|
US11384156B2
(en)
|
2016-07-25 |
2022-07-12 |
The Nemours Foundation |
Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
KR20190034588A
(en)
|
2016-07-28 |
2019-04-02 |
노파르티스 아게 |
Combination therapy of chimeric antigen receptor and PD-1 inhibitor
|
CN110088127A
(en)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
CD155 variant immune modulator and application thereof
|
ES2951552T3
(en)
|
2016-07-29 |
2023-10-23 |
Juno Therapeutics Inc |
Immunomodulatory polypeptides and related compositions and methods
|
AU2017301887A1
(en)
*
|
2016-07-29 |
2019-02-07 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies against anti-CD19 antibodies
|
EP3491152B1
(en)
|
2016-07-29 |
2022-06-29 |
Juno Therapeutics, Inc. |
Methods for assessing the presence or absence of replication competent virus
|
KR20190036551A
(en)
|
2016-08-01 |
2019-04-04 |
노파르티스 아게 |
Treatment of Cancer Using Chimeric Antigen Receptors in Combination with Inhibitors of PRO-M2 Macrophage Molecules
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
WO2018045177A1
(en)
|
2016-09-01 |
2018-03-08 |
Chimera Bioengineering, Inc. |
Gold optimized car t-cells
|
AU2017321894A1
(en)
|
2016-09-02 |
2019-03-14 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with duoCARs
|
US11701384B2
(en)
|
2016-09-02 |
2023-07-18 |
The Regents Of The University Of California |
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
JP2019526269A
(en)
|
2016-09-12 |
2019-09-19 |
ジュノー セラピューティクス インコーポレイテッド |
Perfusion bioreactor bag assembly
|
AU2017332161B2
(en)
|
2016-09-21 |
2024-07-04 |
The United States Government As Represented By The Department Of Veterans Affairs |
Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use
|
JP2020501512A
(en)
*
|
2016-09-23 |
2020-01-23 |
ユニバーシティ オブ サザン カリフォルニア |
Chimeric antigen receptor and compositions thereof and methods of their use
|
EP3518972A4
(en)
|
2016-09-28 |
2020-07-22 |
Kite Pharma, Inc. |
Antigen binding molecules and methods of use thereof
|
WO2018063985A1
(en)
|
2016-09-28 |
2018-04-05 |
Atossa Genetics Inc. |
Methods of adoptive cell therapy
|
CN110139873A
(en)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
HPV specific binding molecules
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
US10525083B2
(en)
|
2016-10-07 |
2020-01-07 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
|
IL292551B2
(en)
|
2016-10-07 |
2023-10-01 |
Tcr2 Therapeutics Inc |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
CN107151654B
(en)
*
|
2016-10-11 |
2020-05-05 |
深圳宾德生物技术有限公司 |
Culture medium of human T lymphocytes and preparation method and application thereof
|
CN107936120B
(en)
*
|
2016-10-13 |
2021-03-09 |
上海赛比曼生物科技有限公司 |
CD19 targeted chimeric antigen receptor and preparation method and application thereof
|
EP4190335A1
(en)
|
2016-10-13 |
2023-06-07 |
Juno Therapeutics, Inc. |
Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
|
JP7181862B2
(en)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
Tumor-infiltrating lymphocytes and methods of treatment
|
JP7149935B2
(en)
|
2016-10-19 |
2022-10-07 |
ザ スクリプス リサーチ インスティテュート |
Chimeric Antigen Receptor Effector Cell Switches with Humanized Targeting Moieties and/or Optimized Chimeric Antigen Receptor Interacting Domains and Uses Thereof
|
SG11201903407XA
(en)
|
2016-10-20 |
2019-05-30 |
Alpine Immune Sciences Inc |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
JP7100028B2
(en)
|
2016-10-20 |
2022-07-12 |
セルジーン コーポレイション |
Cereblon-based heterodimerizable chimeric antigen receptor
|
TWI788307B
(en)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
|
MA46783A
(en)
|
2016-11-03 |
2019-09-11 |
Juno Therapeutics Inc |
T-CELL THERAPY AND BTK INHIBITOR POLYTHERAPY
|
CA3040914A1
(en)
|
2016-11-03 |
2018-05-24 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia inhibitor
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
EP3541847A4
(en)
|
2016-11-17 |
2020-07-08 |
Seattle Genetics, Inc. |
Glycan-interacting compounds and methods of use
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
SG10201912387PA
(en)
|
2016-11-22 |
2020-02-27 |
Nat Univ Singapore |
Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
|
KR20190089005A
(en)
|
2016-11-23 |
2019-07-29 |
노파르티스 아게 |
Methods of enhancing the immune response using everolimus, doxorubicin, or both
|
AU2017368320A1
(en)
*
|
2016-12-02 |
2019-05-02 |
Cartesian Therapeutics, Inc. |
Cancer immuno therapy with highly enriched CD8+ chimeric antigen receptor T cells
|
WO2018102787A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
BR112019011025A2
(en)
|
2016-12-03 |
2019-10-08 |
Juno Therapeutics Inc |
T cell modulation methods
|
MX2019006288A
(en)
|
2016-12-03 |
2020-10-01 |
Juno Therapeutics Inc |
Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors.
|
MA46998A
(en)
|
2016-12-05 |
2019-10-09 |
Juno Therapeutics Inc |
PRODUCTION OF MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
|
CN108165568B
(en)
*
|
2016-12-07 |
2020-12-08 |
上海恒润达生生物科技有限公司 |
Method for culturing CD19CAR-iNKT cells and application
|
CN107058315B
(en)
*
|
2016-12-08 |
2019-11-08 |
上海优卡迪生物医药科技有限公司 |
Strike the siRNA for subtracting people PD-1, recombinant expression CAR-T carrier and its construction method and application
|
CA3045665A1
(en)
|
2016-12-12 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
CN108218994A
(en)
*
|
2016-12-14 |
2018-06-29 |
上海恒润达生生物科技有限公司 |
A kind of method culture T remembers stem cell
|
US11278570B2
(en)
|
2016-12-16 |
2022-03-22 |
B-Mogen Biotechnologies, Inc. |
Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
|
WO2018112415A1
(en)
|
2016-12-16 |
2018-06-21 |
B-Mogen Biotechnologies, Inc. |
ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
|
CN108276493B
(en)
*
|
2016-12-30 |
2023-11-14 |
南京传奇生物科技有限公司 |
Chimeric antigen receptor and application thereof
|
WO2018119518A1
(en)
|
2017-01-01 |
2018-07-05 |
Lee Chi Yu Gregory |
Rp215 chimeric antigen receptor construct and methods of making and using same
|
EP4032550A3
(en)
|
2017-01-05 |
2022-10-19 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor
|
CN110121336A
(en)
|
2017-01-05 |
2019-08-13 |
弗莱德哈钦森癌症研究中心 |
Improve the system and method for efficacy of vaccines
|
EP3346001A1
(en)
*
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
EP3565586A1
(en)
|
2017-01-06 |
2019-11-13 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
CN110462027A
(en)
|
2017-01-06 |
2019-11-15 |
艾欧凡斯生物治疗公司 |
With tumor necrosis factor receptor super family (TNFRSF) agonist amplification tumor infiltrating lymphocyte (TIL) and the therapeutic combination of TIL and TNFRSF agonist
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
CN108285920A
(en)
*
|
2017-01-09 |
2018-07-17 |
上海恒润达生生物科技有限公司 |
A kind of technology and application thereof of vivo detection CART cells expression
|
WO2018132518A1
(en)
|
2017-01-10 |
2018-07-19 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
GB201700553D0
(en)
|
2017-01-12 |
2017-03-01 |
Genagon Therapeutics Ab |
Therapeutic agents
|
US11541076B2
(en)
|
2017-01-13 |
2023-01-03 |
Celdara Medical, Llc |
Chimeric antigen receptors targeting TIM-1
|
MA47325A
(en)
|
2017-01-20 |
2019-11-27 |
Juno Therapeutics Gmbh |
CELL SURFACE CONJUGATES AND CELLULAR COMPOSITIONS AND RELATED METHODS
|
EP3574116A1
(en)
|
2017-01-24 |
2019-12-04 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
CN108342363B
(en)
*
|
2017-01-25 |
2021-02-12 |
北京马力喏生物科技有限公司 |
Transgenic lymphocytes co-expressing anti-MSLN chimeric antigen receptor and immune checkpoint inhibitory molecules and uses thereof
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
RU2674894C2
(en)
*
|
2017-01-30 |
2018-12-13 |
Общество с ограниченной ответственностью "ПЛАНТА" |
New luciferases and methods of their use
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
WO2018144597A1
(en)
*
|
2017-01-31 |
2018-08-09 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods of sensitizing cancer cells to immune cell killing
|
US11649288B2
(en)
|
2017-02-07 |
2023-05-16 |
Seattle Children's Hospital |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
WO2018148671A1
(en)
|
2017-02-12 |
2018-08-16 |
Neon Therapeutics, Inc. |
Hla-based methods and compositions and uses thereof
|
EP3583129B1
(en)
*
|
2017-02-14 |
2021-11-03 |
Kite Pharma, Inc. |
Cd70 binding molecules and methods of use thereof
|
MX2019009552A
(en)
|
2017-02-17 |
2019-10-02 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders.
|
MX2019010171A
(en)
|
2017-02-27 |
2019-10-15 |
Juno Therapeutics Inc |
Compositions, articles of manufacture and methods related to dosing in cell therapy.
|
EP3585880A1
(en)
|
2017-02-27 |
2020-01-01 |
Life Technologies Corporation |
Expansion of populations of t cells by the use of modified serum free media
|
JP7178355B2
(en)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Compositions and methods for CAR T cell therapy
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
MX2019010202A
(en)
|
2017-03-03 |
2019-10-02 |
Seattle Genetics Inc |
Glycan-interacting compounds and methods of use.
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
WO2018161017A1
(en)
*
|
2017-03-03 |
2018-09-07 |
Obsidian Therapeutics, Inc. |
Cd19 compositions and methods for immunotherapy
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
CN110913690A
(en)
|
2017-03-14 |
2020-03-24 |
朱诺治疗学股份有限公司 |
Method for cryogenic storage
|
JP2020511144A
(en)
|
2017-03-16 |
2020-04-16 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
PD-L2 variant immunomodulatory proteins and uses thereof
|
CA3053804A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
BR112019018747A2
(en)
|
2017-03-16 |
2020-05-05 |
Alpine Immune Sciences Inc |
variant immunomodulatory proteins of cd80 and uses thereof
|
WO2018170475A1
(en)
|
2017-03-17 |
2018-09-20 |
Fred Hutchinson Cancer Research Center |
Immunomodulatory fusion proteins and uses thereof
|
WO2018175636A2
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
JP2020515542A
(en)
|
2017-03-23 |
2020-05-28 |
ザ ジェネラル ホスピタル コーポレイション |
CXCR4/CXCR7 blockade and treatment of human papillomavirus-related diseases
|
CA3057838A1
(en)
*
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
KR20240057444A
(en)
|
2017-03-27 |
2024-05-02 |
내셔널 유니버시티 오브 싱가포르 |
Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
|
AU2018245749A1
(en)
|
2017-03-27 |
2019-10-03 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
CA3057372A1
(en)
|
2017-03-31 |
2018-10-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
AU2018243753A1
(en)
|
2017-04-01 |
2019-10-10 |
Avm Biotechnology, Llc |
Replacement of cytotoxic preconditioning before cellular immunotherapy
|
WO2018183921A1
(en)
|
2017-04-01 |
2018-10-04 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
US11357796B2
(en)
|
2017-04-03 |
2022-06-14 |
Kite Pharma, Inc. |
Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cells
|
CA3056261A1
(en)
|
2017-04-07 |
2018-10-11 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
CA3057394A1
(en)
|
2017-04-14 |
2018-10-18 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for transient gene therapy with enhanced stability
|
JP7355650B2
(en)
|
2017-04-14 |
2023-10-03 |
ジュノー セラピューティクス インコーポレイテッド |
Methods for assessing cell surface glycosylation
|
CN108727497A
(en)
*
|
2017-04-17 |
2018-11-02 |
沈阳美达博生物科技有限公司 |
A kind of CD19 antibody and its application
|
WO2018195019A1
(en)
|
2017-04-18 |
2018-10-25 |
The Broad Institute Inc. |
Compositions for detecting secretion and methods of use
|
BR112019021745A2
(en)
|
2017-04-18 |
2020-05-05 |
Fujifilm Cellular Dynamics Inc |
antigen-specific immune effector cells
|
KR20240059648A
(en)
|
2017-04-19 |
2024-05-07 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
Immune cells expressing engineered antigen receptors
|
JOP20180040A1
(en)
|
2017-04-20 |
2019-01-30 |
Gilead Sciences Inc |
Pd-1/pd-l1 inhibitors
|
BR112019021992A2
(en)
|
2017-04-21 |
2020-06-09 |
Kyn Therapeutics |
indole ahr inhibitors and uses thereof
|
JOP20180042A1
(en)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
Humanized Antigen-Binding Domains and Methods of Use
|
CN111032850A
(en)
|
2017-04-27 |
2020-04-17 |
朱诺治疗学有限公司 |
Oligomeric particle reagents and methods of use thereof
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
PT3618842T
(en)
|
2017-05-01 |
2024-01-12 |
Juno Therapeutics Inc |
Combination of a cell therapy and an immunomodulatory compound
|
CN107226867B
(en)
*
|
2017-07-25 |
2018-02-06 |
重庆精准生物技术有限公司 |
The Chimeric antigen receptor of anti human CD 19 antigen and its application
|
WO2018201794A1
(en)
*
|
2017-05-02 |
2018-11-08 |
重庆精准生物技术有限公司 |
Chimeric antigen receptor against human cd19 antigen and application thereof
|
WO2018209115A1
(en)
*
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
AU2018367896B2
(en)
|
2017-05-12 |
2023-06-01 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
CA3062433A1
(en)
|
2017-05-15 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors and their uses
|
US10415017B2
(en)
|
2017-05-17 |
2019-09-17 |
Thunder Biotech, Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
CN110891567B
(en)
|
2017-05-24 |
2024-01-09 |
效应治疗股份有限公司 |
Compositions and methods for improved anti-tumor immune responses
|
EP3406733A1
(en)
|
2017-05-24 |
2018-11-28 |
SIB Swiss Institute of Bioinformatics |
Kinase mutants and uses thereof
|
US11033622B2
(en)
|
2017-05-25 |
2021-06-15 |
Leidos, Inc. |
PD-1 and CTLA-4 dual inhibitor peptides
|
TW201900870A
(en)
|
2017-05-26 |
2019-01-01 |
美商凱特製藥公司 |
Method for preparing and using embryonic mesenchymal precursor cells
|
CA3065126A1
(en)
|
2017-06-01 |
2018-12-06 |
Innovative Cellular Therapeutics CO., LTD. |
Chimeric antigen receptor cell preparation and uses thereof
|
US20200098480A1
(en)
*
|
2017-06-02 |
2020-03-26 |
Mayo Foundation For Medical Education And Research |
System and method for providing clinical outcomes driven expertise for disease treatment
|
US11413310B2
(en)
|
2017-06-02 |
2022-08-16 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
EP3631468A1
(en)
|
2017-06-02 |
2020-04-08 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
US11897953B2
(en)
|
2017-06-14 |
2024-02-13 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
PT3538645T
(en)
|
2017-06-20 |
2021-04-15 |
Inst Curie |
Immune cells defective for suv39h1
|
JP7352473B2
(en)
|
2017-06-21 |
2023-09-28 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
Methods and compositions for chimeric antigen receptors targeting cancer cells
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
JP2020525010A
(en)
|
2017-06-22 |
2020-08-27 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
Methods for producing regulatory immune cells and uses thereof
|
CN110785187B
(en)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
Antibody molecules against CD73 and uses thereof
|
MA49512A
(en)
|
2017-06-28 |
2020-05-06 |
Regeneron Pharma |
HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN-BINDING PROTEINS AND THEIR METHODS OF USE
|
MX2019015155A
(en)
|
2017-06-29 |
2020-08-03 |
Juno Therapeutics Inc |
Mouse model for assessing toxicities associated with immunotherapies.
|
US11235004B2
(en)
|
2017-06-30 |
2022-02-01 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Lymphocyte cell lines and uses thereof
|
WO2019002633A1
(en)
|
2017-06-30 |
2019-01-03 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
Adeno-associated viral vectors for gene therapy
|
CN107287164A
(en)
*
|
2017-07-07 |
2017-10-24 |
青岛协和华美医学诊断技术有限公司 |
Target CD19 Chimeric antigen receptor T cell, preparation method and application
|
CN107365798B
(en)
*
|
2017-07-13 |
2020-07-14 |
山东省齐鲁细胞治疗工程技术有限公司 |
CD19-CAR-T cell carrying iCasp9 suicide gene and application thereof
|
KR20200028447A
(en)
*
|
2017-07-17 |
2020-03-16 |
얀센 바이오테크 인코포레이티드 |
Antigen binding regions for fibronectin type III domains and methods of use thereof
|
CA3070573A1
(en)
|
2017-07-29 |
2019-02-07 |
Juno Therapeutics, Inc. |
Reagents for expanding cells expressing recombinant receptors
|
EP3661964A1
(en)
|
2017-07-31 |
2020-06-10 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
KR20200115450A
(en)
|
2017-08-07 |
2020-10-07 |
더 존스 홉킨스 유니버시티 |
Methods and materials for evaluating and treating cancer
|
EP3664835A1
(en)
|
2017-08-09 |
2020-06-17 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
BR112020001605A2
(en)
|
2017-08-09 |
2020-08-11 |
Juno Therapeutics Inc |
methods for producing genetically modified cell compositions and related compositions
|
WO2019032916A1
(en)
|
2017-08-10 |
2019-02-14 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
BR112020003116A2
(en)
|
2017-08-17 |
2020-08-04 |
Ikena Oncology, Inc. |
ahr inhibitors and their uses
|
MA50057A
(en)
|
2017-09-01 |
2020-07-08 |
Juno Therapeutics Inc |
GENE EXPRESSION AND ASSESSMENT OF A RISK OF DEVELOPING TOXICITY FOLLOWING CELL THERAPY
|
CA3074495A1
(en)
|
2017-09-01 |
2019-03-07 |
Gpb Scientific, Llc |
Methods for preparing therapeutically active cells using microfluidics
|
EP3679370A1
(en)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
EP4035674A1
(en)
|
2017-09-15 |
2022-08-03 |
Kite Pharma, Inc. |
Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking
|
CN107557337B
(en)
*
|
2017-09-15 |
2020-06-26 |
山东兴瑞生物科技有限公司 |
anti-ROR1 safe chimeric antigen receptor modified immune cell and application thereof
|
KR20200044973A
(en)
|
2017-09-15 |
2020-04-29 |
라이프 테크놀로지스 코포레이션 |
Compositions and methods for culturing and expanding cells
|
KR20200067845A
(en)
*
|
2017-09-19 |
2020-06-12 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
Anti-HLA-A2 antibodies and methods of use
|
CN111148533A
(en)
|
2017-09-19 |
2020-05-12 |
麻省理工学院 |
Compositions for chimeric antigen receptor T cell therapy and uses thereof
|
BR112020005519A2
(en)
|
2017-09-20 |
2020-10-27 |
The University Of British Columbia |
new anti-hla-a2 antibodies and their uses
|
CN109517820B
(en)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
gRNA of target HPK1 and HPK1 gene editing method
|
KR102338449B1
(en)
|
2017-09-21 |
2021-12-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Systems, methods, and compositions for targeted nucleic acid editing
|
WO2019060713A1
(en)
|
2017-09-22 |
2019-03-28 |
Kite Pharma, Inc. |
Antigen binding molecules and methods of use thereof
|
IL273432B
(en)
|
2017-09-22 |
2022-09-01 |
Kymera Therapeutics Inc |
Protein degraders and uses thereof
|
US20190092818A1
(en)
|
2017-09-22 |
2019-03-28 |
Kite Pharma, Inc. |
Chimeric polypeptides and uses thereof
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
JP2020536531A
(en)
*
|
2017-09-26 |
2020-12-17 |
ロングウッド ユニバーシティーLongwood University |
PD1-specific chimeric antigen receptor as immunotherapy
|
CN109554349B
(en)
*
|
2017-09-27 |
2022-06-24 |
亘喜生物科技(上海)有限公司 |
Engineered immune cells with silenced PD-1 gene expression
|
WO2019068066A1
(en)
*
|
2017-09-29 |
2019-04-04 |
National Health Research Institutes |
Methods and compositions enhancing survival and functionality of anti-tumor and anti-viral t cells
|
US12043870B2
(en)
|
2017-10-02 |
2024-07-23 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
KR20200104284A
(en)
|
2017-10-03 |
2020-09-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
HPV-specific binding molecule
|
WO2019074892A1
(en)
|
2017-10-09 |
2019-04-18 |
Wisconsin Alumni Research Foundation |
Antibodies targeting glioblastoma stem-like cells and methods of use thereof
|
KR20230020022A
(en)
|
2017-10-10 |
2023-02-09 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
CN111479613A
(en)
|
2017-10-18 |
2020-07-31 |
凯德药业股份有限公司 |
Methods of administering chimeric antigen receptor immunotherapy
|
JP2021501570A
(en)
|
2017-10-18 |
2021-01-21 |
ノバルティス アーゲー |
Compositions and Methods for Selective Proteolysis
|
KR20200085777A
(en)
|
2017-10-18 |
2020-07-15 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Variant ICOS ligand immunomodulatory protein and related compositions and methods
|
CN109694854B
(en)
*
|
2017-10-20 |
2023-11-21 |
亘喜生物科技(上海)有限公司 |
Universal chimeric antigen receptor T cell preparation technology
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
Calling genetic variation from single-cell transcriptomes
|
US20210030793A1
(en)
*
|
2017-10-26 |
2021-02-04 |
St. Jude Children's Research Hospital, Inc. |
Methods and compositions for treating cd33+ cancers and improving in vivo persistence of chimeric antigen receptor t cells
|
US11820823B2
(en)
|
2017-10-27 |
2023-11-21 |
Kite Pharma, Inc. |
T cell receptor antigen binding molecules and methods of use thereof
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
MA49911A
(en)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
ANTIBODIES AND CHEMERICAL ANTIGENIC RECEPTORS SPECIFIC TO THE B-LYMPHOCYTE MATURATION ANTIGEN
|
MA50860A
(en)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
CHEMERICAL RECEPTERS OF ANTIGEN AGAINST B-CELL MATURATION ANTIGEN AND CODING POLYNUCLEOTIDES
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
CA3081456A1
(en)
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
MA50855A
(en)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
PROCESS FOR GENERATING THERAPEUTIC COMPOSITIONS OF MODIFIED CELLS
|
MX2020004239A
(en)
|
2017-11-01 |
2020-09-09 |
Juno Therapeutics Inc |
Process for producing a t cell composition.
|
US10428141B2
(en)
*
|
2017-11-03 |
2019-10-01 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-ROR1 immunotherapy
|
JP2021502077A
(en)
|
2017-11-06 |
2021-01-28 |
エディタス・メディシン,インコーポレイテッド |
Methods, compositions and components for CRISPR-CAS9 editing of CBLB on T cells for immunotherapy
|
MX2020004568A
(en)
|
2017-11-06 |
2020-10-05 |
Juno Therapeutics Inc |
Combination of a cell therapy and a gamma secretase inhibitor.
|
KR20200085780A
(en)
*
|
2017-11-07 |
2020-07-15 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
LILRB4 targeting with CAR-T or CAR-NK cells in the treatment of cancer
|
EP3707160A1
(en)
|
2017-11-10 |
2020-09-16 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Chimeric antigen receptors targeting tumor antigens
|
EP3706904A1
(en)
|
2017-11-10 |
2020-09-16 |
Juno Therapeutics, Inc. |
Closed-system cryogenic vessels
|
WO2019094983A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
|
WO2019099440A1
(en)
|
2017-11-14 |
2019-05-23 |
Arcellx, Inc. |
Multifunctional immune cell therapies
|
BR112020009136A2
(en)
|
2017-11-14 |
2020-10-13 |
Arcellx, Inc. |
polypeptides that contain domain and uses thereof
|
TW201922774A
(en)
|
2017-11-15 |
2019-06-16 |
瑞士商諾華公司 |
BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
|
WO2019099707A1
(en)
|
2017-11-16 |
2019-05-23 |
Kite Pharma, Inc |
Modified chimeric antigen receptors and methods of use
|
JP2021503885A
(en)
*
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Expanded culture of peripheral blood lymphocytes (PBL) from peripheral blood
|
CN109837244A
(en)
*
|
2017-11-25 |
2019-06-04 |
深圳宾德生物技术有限公司 |
A kind of Chimeric antigen receptor T cell and its preparation method and application for the targeting CD19 knocking out PD1
|
EP3717907A1
(en)
|
2017-11-30 |
2020-10-07 |
Novartis AG |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
MA51210A
(en)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
METHODS FOR DOSING AND MODULATING GENETICALLY MODIFIED CELLS
|
CA3122010A1
(en)
*
|
2017-12-04 |
2019-06-13 |
Coare Holdings, Inc. |
Anti-dclk1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
|
EP3720949A1
(en)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
US20200384025A1
(en)
|
2017-12-08 |
2020-12-10 |
Juno Therapeutics, Inc. |
Process for producing a composition of engineered t cells
|
AU2018379094A1
(en)
|
2017-12-08 |
2020-06-25 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
US20210369775A1
(en)
|
2017-12-15 |
2021-12-02 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
US12006356B2
(en)
|
2017-12-15 |
2024-06-11 |
Juno Therapeutics, Inc. |
Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
|
WO2019117976A1
(en)
|
2017-12-17 |
2019-06-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Peptide hydrogels and use thereof
|
WO2019126186A1
(en)
|
2017-12-18 |
2019-06-27 |
Neon Therapeutics, Inc. |
Neoantigens and uses thereof
|
CN108018312B
(en)
*
|
2017-12-20 |
2019-09-10 |
上海优卡迪生物医药科技有限公司 |
The CAR-T therapy vector and its construction method of a kind of T lymphocyte leukaemia and application
|
CN111566120B
(en)
|
2017-12-20 |
2023-09-29 |
捷克共和国有机化学与生物化学研究所 |
3' cyclic dinucleotides with phosphonate bonds of activated STING adaptor protein
|
AU2018392212B9
(en)
|
2017-12-20 |
2021-03-18 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
|
GB201721833D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Cancer Research Tech Ltd |
Fusion proteins
|
US10874743B2
(en)
|
2017-12-26 |
2020-12-29 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
CN109970864A
(en)
*
|
2017-12-28 |
2019-07-05 |
上海细胞治疗研究院 |
A kind of two-way activation costimulatory molecules receptor and application thereof
|
CN109971712B
(en)
*
|
2017-12-28 |
2023-06-20 |
上海细胞治疗研究院 |
CAR-T cell specifically targeting CD19 antigen and stably expressing PD-1 antibody at high level and application thereof
|
CN109970866B
(en)
*
|
2017-12-28 |
2022-10-04 |
上海细胞治疗研究院 |
CD28 bidirectional activation co-stimulatory molecule receptor and application thereof
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
EP3735255A4
(en)
*
|
2018-01-05 |
2021-09-22 |
Maxcyte, Inc. |
Chronic car treatment for cancer
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
WO2019139972A1
(en)
|
2018-01-09 |
2019-07-18 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
US10561686B2
(en)
|
2018-01-12 |
2020-02-18 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
EP3586852B8
(en)
*
|
2018-01-11 |
2021-04-28 |
Innovative Cellular Therapeutics Inc. |
Modified cell expansion and uses thereof
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
BR112020014446A2
(en)
|
2018-01-15 |
2020-12-29 |
Pfizer Inc. |
METHODS FOR ADMINISTERING CHEMICAL ANTIGEN RECEPTOR IMMUNOTHERAPY IN COMBINATION WITH A 4-1BB AGONIST
|
TW201940182A
(en)
|
2018-01-22 |
2019-10-16 |
美商安德賽特公司 |
Methods of use for CAR T cells
|
BR112020015328A2
(en)
|
2018-01-29 |
2020-12-08 |
Merck Patent Gmbh |
GCN2 INHIBITORS AND USES OF THE SAME
|
TW201940481A
(en)
|
2018-01-29 |
2019-10-16 |
美商維泰克斯製藥公司 |
GCN2 inhibitors and uses thereof
|
KR102115236B1
(en)
*
|
2018-01-29 |
2020-05-27 |
(주)에스엠티바이오 |
Chimera antigen receptors for treating pancreatic cancer or biliary tract cancer
|
US20210069246A1
(en)
|
2018-01-31 |
2021-03-11 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
WO2019152747A1
(en)
|
2018-01-31 |
2019-08-08 |
Juno Therapeutics, Inc. |
Methods and reagents for assessing the presence or absence of replication competent virus
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
WO2019152957A1
(en)
|
2018-02-02 |
2019-08-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Dna-chimeric antigen receptor t cells for immunotherapy
|
US20210087511A1
(en)
*
|
2018-02-09 |
2021-03-25 |
Global Life Sciences Solutions Usa Llc |
Bioprocessing methods for cell therapy
|
CN111094358A
(en)
*
|
2018-02-11 |
2020-05-01 |
江苏恒瑞医药股份有限公司 |
Separated chimeric antigen receptor, modified T cell containing same and application
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
CN110157677A
(en)
*
|
2018-02-12 |
2019-08-23 |
深圳宾德生物技术有限公司 |
A kind of targeting T lymphocyte and its preparation method and application
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
IL300572A
(en)
|
2018-02-13 |
2023-04-01 |
Gilead Sciences Inc |
Pd-1/pd-l1 inhibitors
|
EP3752531A1
(en)
|
2018-02-14 |
2020-12-23 |
Kite Pharma, Inc. |
Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
|
CN112534044A
(en)
|
2018-02-16 |
2021-03-19 |
凯德药业股份有限公司 |
Modified pluripotent stem cells and methods of making and using
|
KR20200144093A
(en)
|
2018-02-17 |
2020-12-28 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
Compositions and methods for membrane protein delivery
|
CN112119157A
(en)
|
2018-03-06 |
2020-12-22 |
宾夕法尼亚大学董事会 |
Prostate specific membrane antigen CAR and methods of use thereof
|
US20210046159A1
(en)
|
2018-03-09 |
2021-02-18 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
WO2019175328A1
(en)
|
2018-03-14 |
2019-09-19 |
Imba - Institut Für Molekulare Biotechnologie Gmbh |
Bh4pathwayactivationandusethereoffortreatingcancer
|
CA3093915A1
(en)
|
2018-03-15 |
2019-09-19 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
EP3765094A4
(en)
|
2018-03-15 |
2021-12-22 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
DE102018108612A1
(en)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
METHOD FOR INCREASING PERSISTENCE OF ADOPTIVELY INFUNDED T CELLS
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
BR112020020245A2
(en)
|
2018-04-05 |
2021-04-06 |
Editas Medicine, Inc. |
METHODS OF PRODUCING CELLS EXPRESSING A RECOMBINANT RECEIVER AND RELATED COMPOSITIONS
|
CN112566698A
(en)
|
2018-04-05 |
2021-03-26 |
朱诺治疗学股份有限公司 |
T cell receptor and engineered cells expressing the same
|
TWI818007B
(en)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-cyclic dinucleotides
|
TWI833744B
(en)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-cyclic dinucleotides
|
TW202005654A
(en)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
2'2'-cyclic dinucleotides
|
AU2019251473A1
(en)
|
2018-04-10 |
2020-10-22 |
Amgen Inc. |
Chimeric receptors to DLL3 and methods of use thereof
|
TWI723374B
(en)
|
2018-04-12 |
2021-04-01 |
美商凱特製藥公司 |
Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
|
CA3096500A1
(en)
|
2018-04-13 |
2019-10-17 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
US20210079384A1
(en)
|
2018-04-13 |
2021-03-18 |
The Johns Hopkins University |
Non-invasive detection of response to a targeted therapy
|
WO2019200252A1
(en)
|
2018-04-13 |
2019-10-17 |
The Johns Hopkins University |
Non-invasive detection of response to immunotherapy
|
AR115051A1
(en)
|
2018-04-16 |
2020-11-25 |
Univ Texas |
HUMAN QUINURENINASE ENZYMES AND THEIR USES
|
CN112292128A
(en)
|
2018-04-16 |
2021-01-29 |
阿瑞斯医疗有限公司 |
EP4 inhibitors and uses thereof
|
US10869888B2
(en)
*
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
US11945878B2
(en)
|
2018-04-18 |
2024-04-02 |
Abclon Inc. |
Switch molecule and switchable chimeric antigen receptor
|
US20210161958A1
(en)
*
|
2018-04-19 |
2021-06-03 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating melanoma with a chimeric antigen receptor
|
US10899735B2
(en)
|
2018-04-19 |
2021-01-26 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
TW202010744A
(en)
|
2018-04-24 |
2020-03-16 |
美商維泰克斯製藥公司 |
Pteridinone compounds and uses thereof
|
SI3784666T1
(en)
|
2018-04-24 |
2022-07-29 |
Merck Patent Gmbh |
Antiproliferation compounds and uses thereof
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
CN112312930A
(en)
*
|
2018-05-02 |
2021-02-02 |
宾夕法尼亚大学董事会 |
Compositions and methods for phospholipase A2 receptor chimeric autoantibody receptor T cells
|
TW202014193A
(en)
|
2018-05-03 |
2020-04-16 |
捷克科學院有機化學與生物化學研究所 |
2’3’-cyclic dinucleotides comprising carbocyclic nucleotide
|
CN108753774B
(en)
*
|
2018-05-03 |
2021-03-30 |
山东省齐鲁细胞治疗工程技术有限公司 |
CD19-CAR-T cell interfering with IL-6 expression and application thereof
|
CN112584902A
(en)
|
2018-05-03 |
2021-03-30 |
朱诺治疗学股份有限公司 |
Combination therapy of Chimeric Antigen Receptor (CAR) T cell therapy and kinase inhibitors
|
CN112424342A
(en)
|
2018-05-08 |
2021-02-26 |
生命科技公司 |
Compositions and methods for culturing and expanding cells
|
BR112020022879A2
(en)
|
2018-05-11 |
2021-02-23 |
Crispr Therapeutics Ag |
methods and compositions for cancer treatment
|
KR102666717B1
(en)
|
2018-05-14 |
2024-05-20 |
길리애드 사이언시즈, 인코포레이티드 |
Mcl-1 inhibitors
|
JP2021525069A
(en)
|
2018-05-18 |
2021-09-24 |
ザ ジョンズ ホプキンス ユニバーシティ |
Cell-free DNA for assessing and / or treating cancer
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
TW202015726A
(en)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
CN108715859B
(en)
*
|
2018-05-31 |
2021-08-03 |
中国医学科学院血液病医院(中国医学科学院血液学研究所) |
Chimeric antigen receptor targeting CD22 and application thereof
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
CA3101856A1
(en)
|
2018-06-01 |
2019-12-05 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
CU20200089A7
(en)
|
2018-06-01 |
2021-07-02 |
Novartis Ag |
BINDING MOLECULES AGAINST BCMA
|
CA3101991A1
(en)
*
|
2018-06-01 |
2019-12-05 |
Mayo Foundation For Medical Education And Research |
Materials and methods for treating cancer
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
SG11202011830SA
(en)
|
2018-06-13 |
2020-12-30 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
KR20190141511A
(en)
*
|
2018-06-14 |
2019-12-24 |
주식회사 녹십자랩셀 |
New peptide, chemeric antigen receptor and immune cell expressing the same
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
CA3104288A1
(en)
|
2018-06-21 |
2019-12-26 |
B-Mogen Biotechnologies, Inc. |
Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
WO2019243888A1
(en)
|
2018-06-22 |
2019-12-26 |
Kite Pharma Eu B.V. |
Compositions and methods for making engineered t cells
|
AU2019299439A1
(en)
|
2018-07-03 |
2021-01-21 |
Sotio, LLC |
Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
AR116109A1
(en)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
|
PE20210642A1
(en)
|
2018-07-13 |
2021-03-23 |
Gilead Sciences Inc |
PD-1 / PD-L1 INHIBITORS
|
WO2020017479A1
(en)
|
2018-07-17 |
2020-01-23 |
ノイルイミューン・バイオテック株式会社 |
Anti-gpc3 single-chain antibody-containing car
|
KR20210033025A
(en)
|
2018-07-18 |
2021-03-25 |
암젠 인크 |
Chimeric receptor for STEAP1 and methods of use thereof
|
ES2973946T3
(en)
|
2018-07-19 |
2024-06-25 |
Regeneron Pharma |
Chimeric antigen receptors with specificity for BCMA and uses thereof
|
JP2021532116A
(en)
|
2018-07-23 |
2021-11-25 |
マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. |
Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
|
CN108949759B
(en)
*
|
2018-07-23 |
2021-06-01 |
合肥一兮生物科技有限公司 |
siRNA for knocking down human IL-15, CD19CAR expression vector, CAR-T cell, construction method and application
|
CN112533953A
(en)
|
2018-08-02 |
2021-03-19 |
凯德药业股份有限公司 |
Chimeric antigen receptor therapy T cell expansion kinetics and uses thereof
|
US20210163893A1
(en)
|
2018-08-09 |
2021-06-03 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
EP3833759A1
(en)
|
2018-08-09 |
2021-06-16 |
Juno Therapeutics, Inc. |
Methods for assessing integrated nucleic acids
|
CN113366017B
(en)
|
2018-08-10 |
2024-05-28 |
优特力克斯有限公司 |
HLA-DR binding chimeric antigen receptor and CAR-T cells
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
WO2020041384A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
3-phenyl-2-cyano-azetidine derivatives, inhibitors of rna-guided nuclease activity
|
US20210177832A1
(en)
|
2018-08-20 |
2021-06-17 |
The Broad Institute, Inc. |
Inhibitors of rna-guided nuclease target binding and uses thereof
|
CN110856724B
(en)
*
|
2018-08-24 |
2022-05-27 |
杭州康万达医药科技有限公司 |
Therapeutic agents comprising nucleic acids and CAR-modified immune cells and uses thereof
|
SG11202101994XA
(en)
|
2018-08-28 |
2021-03-30 |
Vor Biopharma Inc |
Genetically engineered hematopoietic stem cells and uses thereof
|
SG11202101455TA
(en)
|
2018-08-28 |
2021-03-30 |
Hutchinson Fred Cancer Res |
Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
|
US20220348682A1
(en)
|
2018-08-30 |
2022-11-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
AU2019327490A1
(en)
|
2018-08-30 |
2021-03-25 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
US11866494B2
(en)
*
|
2018-08-31 |
2024-01-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
CAR T therapy through uses of co-stimulation
|
US20220364055A1
(en)
|
2018-08-31 |
2022-11-17 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US12030875B2
(en)
|
2018-09-07 |
2024-07-09 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
CN113167796A
(en)
|
2018-09-11 |
2021-07-23 |
朱诺治疗学股份有限公司 |
Methods for performing mass spectrometry on engineered cell compositions
|
SG11202102644XA
(en)
|
2018-09-19 |
2021-04-29 |
Alpine Immune Sciences Inc |
Methods and uses of variant cd80 fusion proteins and related constructs
|
CA3155291A1
(en)
|
2018-09-24 |
2020-04-02 |
The Medical College Of Wisconsin, Inc. |
Anti-cd30 antibodies and methods of use
|
US20210347851A1
(en)
*
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
JP2022502037A
(en)
|
2018-09-28 |
2022-01-11 |
マサチューセッツ インスティテュート オブ テクノロジー |
Immunomodulatory molecules localized to collagen and their methods
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
WO2020072536A1
(en)
|
2018-10-01 |
2020-04-09 |
Adicet Bio, Inc. |
COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
EP3488851A1
(en)
|
2018-10-03 |
2019-05-29 |
AVM Biotechnology, LLC |
Immunoablative therapies
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
US11851663B2
(en)
|
2018-10-14 |
2023-12-26 |
Snipr Biome Aps |
Single-vector type I vectors
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
AU2018447127A1
(en)
|
2018-10-22 |
2021-05-27 |
Shanghai GenBase Biotechnology Co., Ltd. |
Anti-CLDN128.2 antibody and uses thereof
|
KR20210093908A
(en)
|
2018-10-23 |
2021-07-28 |
리제너론 파아마슈티컬스, 인크. |
NY-ESO-1 T cell receptor and methods of use thereof
|
AU2019366355B2
(en)
|
2018-10-24 |
2022-10-13 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
EP3870146A4
(en)
*
|
2018-10-25 |
2022-08-10 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Increase or maintaining t-cell subpopulations in adoptive t-cell therapy
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
WO2020092057A1
(en)
|
2018-10-30 |
2020-05-07 |
Yale University |
Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
US20220002669A1
(en)
|
2018-10-31 |
2022-01-06 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
CN113227089B
(en)
|
2018-10-31 |
2024-07-05 |
吉利德科学公司 |
Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
|
KR20210113169A
(en)
|
2018-11-01 |
2021-09-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Treatment method using chimeric antigen receptor specific for Β cell maturation antigen
|
ES2968737T3
(en)
|
2018-11-06 |
2024-05-13 |
Juno Therapeutics Inc |
Process to produce genetically engineered T cells
|
EP3876950A4
(en)
*
|
2018-11-07 |
2022-11-30 |
SOTIO Biotech Inc. |
Anti-gpc3 chimeric antigen receptors (cars) in combination with trans co-stimulatory molecules and therapeutic uses thereof
|
CN109467604A
(en)
*
|
2018-11-07 |
2019-03-15 |
南京卡提医学科技有限公司 |
Chimeric antigen receptor DAP12-T2A-CD8 α-CD19scFv-TREM1 and application thereof
|
CN109503717A
(en)
*
|
2018-11-07 |
2019-03-22 |
南京卡提医学科技有限公司 |
Chimeric antigen receptor DAP12-T2A-CD8 α-CD19scfv-NKp44 and application thereof
|
CA3117978A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
JP2022507453A
(en)
|
2018-11-14 |
2022-01-18 |
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド |
Fusosome composition for T cell delivery
|
BR112021009420A2
(en)
|
2018-11-16 |
2021-11-23 |
Juno Therapeutics Inc |
Engineered t-cell dosing methods for the treatment of b-cell malignancies
|
EP3883955A1
(en)
|
2018-11-19 |
2021-09-29 |
Board of Regents, The University of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
US20220031749A1
(en)
|
2018-11-28 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
BR112021010248A2
(en)
|
2018-11-29 |
2021-08-17 |
Board Of Regents, The University Of Texas System |
methods for ex vivo expansion of natural killer cells and their use
|
US20220088070A1
(en)
|
2018-11-30 |
2022-03-24 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
JP2022516401A
(en)
|
2018-11-30 |
2022-02-28 |
カイメラ セラピューティクス, インコーポレイテッド |
IRAK Degradants and Their Use
|
EP3886894B1
(en)
|
2018-11-30 |
2024-03-13 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
|
WO2020117952A2
(en)
|
2018-12-05 |
2020-06-11 |
Genentech, Inc. |
Diagnostic methods and compositions for cancer immunotherapy
|
TW202100747A
(en)
*
|
2018-12-07 |
2021-01-01 |
中國大陸商亘喜生物科技(上海)有限公司 |
Compositions and methods for immunotherapy
|
KR20210101270A
(en)
|
2018-12-10 |
2021-08-18 |
암젠 인크 |
Mutant piggyback transposase
|
US20220056092A1
(en)
|
2018-12-11 |
2022-02-24 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
BR112021012172A2
(en)
|
2018-12-12 |
2021-08-31 |
Kite Pharma, Inc. |
CHIMERIC AND T-CELL ANTIGEN RECEPTORS AND METHODS OF USE
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
EP3670530A1
(en)
|
2018-12-18 |
2020-06-24 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
CN113271945A
(en)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
Dosing regimens and pharmaceutical combinations comprising 3- (1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives
|
EP3899954A4
(en)
|
2018-12-21 |
2022-09-14 |
BioNTech US Inc. |
Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
US20220090132A1
(en)
*
|
2019-01-06 |
2022-03-24 |
Abintus Bio, Inc. |
Car t cell methods and constructs
|
EP3917570A1
(en)
|
2019-01-29 |
2021-12-08 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
CN117264064A
(en)
|
2019-02-04 |
2023-12-22 |
米纳瓦生物技术公司 |
anti-NME antibodies and methods of treating cancer or cancer metastasis
|
KR20210118945A
(en)
|
2019-02-15 |
2021-10-01 |
유니버시티 오브 써던 캘리포니아 |
LYM-1 and LYM-2 Antibody Compositions and Improved CAR Constructs
|
EA202192029A1
(en)
|
2019-02-15 |
2021-10-27 |
Новартис Аг |
SUBSTITUTED DERIVATIVES OF 3- (1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE AND VARIANTS OF THEIR APPLICATION
|
KR20210129671A
(en)
|
2019-02-15 |
2021-10-28 |
노파르티스 아게 |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
SG11202107825WA
(en)
|
2019-02-25 |
2021-09-29 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
MX2021010288A
(en)
*
|
2019-03-01 |
2021-09-23 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof.
|
MX2021010441A
(en)
|
2019-03-01 |
2021-09-21 |
Allogene Therapeutics Inc |
Dll3 targeting chimeric antigen receptors and binding agents.
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
WO2020178769A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
US20220143061A1
(en)
|
2019-03-07 |
2022-05-12 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
BR112021017744A2
(en)
|
2019-03-08 |
2021-11-16 |
Obsidian Therapeutics Inc |
CD40L Compositions and Methods for Adjustable Regulation
|
CA3128971A1
(en)
|
2019-03-08 |
2020-09-17 |
Klinikum Der Universitat Munchen |
Ccr8 expressing lymphocytes for targeted tumor therapy
|
US20220154282A1
(en)
|
2019-03-12 |
2022-05-19 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
US20220142948A1
(en)
|
2019-03-18 |
2022-05-12 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
SG11202109066RA
(en)
|
2019-03-19 |
2021-09-29 |
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Hebron |
Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
|
US20230074800A1
(en)
|
2019-03-21 |
2023-03-09 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
SG11202110828UA
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Ltd |
Bicycle toxin conjugates and uses thereof
|
TW202106676A
(en)
|
2019-04-05 |
2021-02-16 |
美商凱麥拉醫療公司 |
Stat degraders and uses thereof
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
TWI751516B
(en)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
Solid forms of a toll-like receptor modulator
|
TWI751517B
(en)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
Solid forms of a toll-like receptor modulator
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
BR112021021178A2
(en)
|
2019-04-26 |
2022-03-15 |
Allogene Therapeutics Inc |
Rituximab-resistant chimeric antigen receptors and uses thereof
|
KR20220004028A
(en)
|
2019-04-26 |
2022-01-11 |
알로젠 테라퓨틱스 인코포레이티드 |
Methods for making allogeneic CAR T cells
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
CN114007642A
(en)
|
2019-04-30 |
2022-02-01 |
森迪生物科学公司 |
Chimeric receptors and methods of use thereof
|
CA3136742A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
MX2021013219A
(en)
|
2019-05-01 |
2022-02-17 |
Juno Therapeutics Inc |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods.
|
SG11202112123RA
(en)
|
2019-05-03 |
2021-11-29 |
Kite Pharma Inc |
Methods of administering chimeric antigen receptor immunotherapy
|
CN118184800A
(en)
|
2019-05-07 |
2024-06-14 |
亘喜生物科技(上海)有限公司 |
Engineered immune cells targeting BCMA and uses thereof
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
US11407829B2
(en)
|
2019-05-22 |
2022-08-09 |
Leidos, Inc. |
LAG3 binding peptides
|
US20220251538A1
(en)
|
2019-05-23 |
2022-08-11 |
Matjaz Vogelsang |
Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
|
TWI826690B
(en)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
Substituted eneoxindoles and uses thereof
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
MX2021014441A
(en)
|
2019-05-31 |
2022-01-06 |
Ikena Oncology Inc |
Tead inhibitors and uses thereof.
|
EP4023230A4
(en)
*
|
2019-06-05 |
2023-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody cleavage site-binding molecule
|
JP2022535380A
(en)
|
2019-06-07 |
2022-08-08 |
ジュノー セラピューティクス インコーポレイテッド |
Automated T cell culture
|
WO2020252404A1
(en)
|
2019-06-12 |
2020-12-17 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
EP3983538A1
(en)
|
2019-06-12 |
2022-04-20 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
KR20220034782A
(en)
|
2019-06-12 |
2022-03-18 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Combination therapy of cell-mediated cytotoxicity therapy and pro-survival BLC2 family protein inhibitors
|
AU2020296878B2
(en)
|
2019-06-21 |
2023-04-20 |
Kite Pharma, Inc. |
TGF-beta receptors and methods of use
|
WO2020264019A1
(en)
|
2019-06-24 |
2020-12-30 |
Children's Hospital Los Angeles |
Bcl11b overexpression to enhance human thymopoiesis and t cell function
|
BR112021026376A2
(en)
|
2019-06-25 |
2022-05-10 |
Gilead Sciences Inc |
flt3l-fc fusion proteins and methods of use
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
CN114729383A
(en)
|
2019-07-02 |
2022-07-08 |
弗莱德哈钦森癌症研究中心 |
Recombinant AD35 vectors and related gene therapy improvements
|
WO2021003297A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
GB201909573D0
(en)
|
2019-07-03 |
2019-08-14 |
Cancer Research Tech Ltd |
Modulation of T cell cytotoxicity and related therapy
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
US20220267726A1
(en)
|
2019-07-18 |
2022-08-25 |
Gpb Scientific, Inc. |
Ordered processing of blood products to produce therapeutically active cells
|
CA3146895A1
(en)
|
2019-07-23 |
2021-01-28 |
Mnemo Therapeutics |
Immune cells defective for suv39h1
|
CN114174345A
(en)
|
2019-07-24 |
2022-03-11 |
瑞泽恩制药公司 |
Chimeric antigen receptor with MAGE-A4 specificity and uses thereof
|
CN110305849B
(en)
*
|
2019-08-01 |
2021-03-30 |
广东万海细胞生物科技有限公司 |
T cell capable of stably expressing CAR (CAR), preparation method and application thereof
|
GB201911066D0
(en)
|
2019-08-02 |
2019-09-18 |
Achilles Therapeutics Ltd |
T cell therapy
|
EP4010377A4
(en)
*
|
2019-08-09 |
2023-09-06 |
A2 Biotherapeutics, Inc. |
Cell-surface receptors responsive to loss of heterozygosity
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
US20220298222A1
(en)
|
2019-08-22 |
2022-09-22 |
Juno Therapeutics, Inc. |
Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
|
US20220392613A1
(en)
|
2019-08-30 |
2022-12-08 |
Juno Therapeutics, Inc. |
Machine learning methods for classifying cells
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
MX2022002578A
(en)
|
2019-09-02 |
2022-06-02 |
Inst Curie |
Immunotherapy targeting tumor neoantigenic peptides.
|
BR112022003852A2
(en)
|
2019-09-03 |
2022-05-31 |
Allogene Therapeutics Inc |
Methods of preparing t cells for t cell therapy
|
CA3152525A1
(en)
|
2019-09-03 |
2021-03-11 |
Sana Biotechnology, Inc. |
Cd24-associated particles and related methods and uses thereof
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
US20230081117A1
(en)
|
2019-09-09 |
2023-03-16 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
AU2020345943A1
(en)
|
2019-09-10 |
2022-03-31 |
Obsidian Therapeutics, Inc. |
CA2-IL15 fusion proteins for tunable regulation
|
CA3150108A1
(en)
|
2019-09-13 |
2021-03-18 |
Neelu Kaila |
Hpk1 antagonists and uses thereof
|
WO2021051088A1
(en)
*
|
2019-09-13 |
2021-03-18 |
Ohio State Innovation Foundation |
Nk cell immunotherapy compositions, methods of making and methods of using same
|
JP2022548881A
(en)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
|
JP2023501871A
(en)
|
2019-09-20 |
2023-01-20 |
上海吉倍生物技術有限公司 |
BCMA targeting antibodies and chimeric antigen receptors
|
EP4031654A4
(en)
*
|
2019-09-20 |
2023-11-22 |
The University of North Carolina at Chapel Hill |
Modified t cells and methods of preparing the same
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
KR102287180B1
(en)
*
|
2019-10-01 |
2021-08-09 |
충북대학교 산학협력단 |
Chimeric Antigen Receptor Specifically Binding to CD138, Immune Cell Expressing the Same, and Anti-Cancer Use Thereof
|
CN115103910A
(en)
|
2019-10-03 |
2022-09-23 |
工匠开发实验室公司 |
CRISPR system with engineered dual guide nucleic acids
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
AU2020365113A1
(en)
|
2019-10-18 |
2022-04-07 |
Forty Seven, Inc. |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
EP4048304A1
(en)
|
2019-10-22 |
2022-08-31 |
Institut Curie |
Immunotherapy targeting tumor neoantigenic peptides
|
CN110679588A
(en)
*
|
2019-10-23 |
2020-01-14 |
厦门生命互联科技有限公司 |
Chimeric antigen receptor T cell cryopreservation medium and application thereof
|
WO2021081330A1
(en)
|
2019-10-23 |
2021-04-29 |
Kite Pharma, Inc. |
Anti-idiotypic antigen binding molecules and methods of use thereof
|
TWI717880B
(en)
|
2019-10-24 |
2021-02-01 |
中國醫藥大學附設醫院 |
Hla-g specific chimeric antigen receptor, nucleic acid, hla-g specific chimeric antigen receptor expression plasmid, hla-g specific chimeric antigen receptor expressing cell, use thereof and pharmaceutical composition for treating cancer
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
JP2023500318A
(en)
|
2019-10-30 |
2023-01-05 |
ジュノ セラピューティクス ゲーエムベーハー |
Cell selection and/or cell stimulation devices and methods of use
|
KR20220091576A
(en)
|
2019-10-31 |
2022-06-30 |
포티 세븐, 인코포레이티드 |
Anti-CD47 and Anti-CD20 Based Treatment of Hematological Cancers
|
US20220403002A1
(en)
|
2019-11-01 |
2022-12-22 |
Kyoto Prefectural Public University Corporation |
B-cell antibody receptor and use thereof
|
CN114980918A
(en)
|
2019-11-07 |
2022-08-30 |
朱诺治疗学股份有限公司 |
Combination of T cell therapy with (S) -3- [4- (4-morpholin-4-ylmethyl-benzyloxy) -1-oxo-1, 3-dihydro-isoindol-2-yl ] -piperidine-2, 6-dione
|
TWI778443B
(en)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1 inhibitors
|
BR112022009521A2
(en)
|
2019-11-20 |
2022-08-16 |
Gi Cell Inc |
COMPOSITION OF MEDIUM FOR T-CELL CULTURE AND METHOD FOR T-CELL CULTURE USING THE SAME
|
AR120566A1
(en)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
|
AU2020394424A1
(en)
|
2019-11-26 |
2022-06-16 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
CN114945382A
(en)
|
2019-11-26 |
2022-08-26 |
诺华股份有限公司 |
CD19 and CD22 chimeric antigen receptors and uses thereof
|
WO2021113776A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
|
MX2022006715A
(en)
|
2019-12-06 |
2022-09-23 |
Juno Therapeutics Inc |
Methods related to toxicity and response associated with cell therapy for treating b cell malignancies.
|
KR20220122656A
(en)
|
2019-12-06 |
2022-09-02 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Anti-idiotypic Antibodies and Related Compositions and Methods Against GPDAC5D-Targeting Binding Domain
|
TW202136251A
(en)
|
2019-12-17 |
2021-10-01 |
美商凱麥拉醫療公司 |
Irak degraders and uses thereof
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
EP4076660A1
(en)
|
2019-12-20 |
2022-10-26 |
Novartis AG |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
IL294150A
(en)
|
2019-12-23 |
2022-08-01 |
Kymera Therapeutics Inc |
Smarca degraders and uses thereof
|
CN117736207A
(en)
|
2019-12-24 |
2024-03-22 |
卡尔那生物科学株式会社 |
Diacylglycerol kinase modulating compounds
|
JP7088902B2
(en)
*
|
2019-12-27 |
2022-06-21 |
クレージュ メディカル カンパニー,リミテッド |
Nucleic acid encoding the chimeric antigen receptor protein and T lymphocytes expressing the chimeric antigen receptor protein
|
AU2020411478A1
(en)
|
2019-12-28 |
2022-07-14 |
Zeon Corporation |
Microfluidic cartridges for processing particles and cells
|
CN113150167A
(en)
*
|
2020-01-22 |
2021-07-23 |
中国人民解放军总医院第五医学中心 |
CAR T cell structure EM1 design capable of reversing PD-1 immunosuppressive signal
|
AU2021211713A1
(en)
|
2020-01-23 |
2022-08-25 |
The Children's Medical Center Corporation |
Stroma-free T cell differentiation from human pluripotent stem cells
|
JP2023511417A
(en)
|
2020-01-24 |
2023-03-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Antigens Preferentially Expressed in Melanoma (PRAME) T Cell Receptors and Methods of Their Use
|
KR20220145341A
(en)
|
2020-01-24 |
2022-10-28 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Methods of Administration and Treatment of Follicular Lymphoma and Marginal Zone Lymphoma in Adoptive Cell Therapy
|
US20230090117A1
(en)
|
2020-01-28 |
2023-03-23 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
WO2021155897A1
(en)
|
2020-02-03 |
2021-08-12 |
MVZ Prof. Niendorf Pathologie Hamburg-West GmbH |
Marker set for the diagnosis and treatment of cancer
|
CA3169672A1
(en)
|
2020-02-12 |
2021-08-19 |
Juno Therapeutics, Inc. |
Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
EP4103203A1
(en)
|
2020-02-12 |
2022-12-21 |
Juno Therapeutics, Inc. |
Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
CR20220396A
(en)
|
2020-02-14 |
2022-11-14 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
KR20220146530A
(en)
|
2020-02-27 |
2022-11-01 |
노파르티스 아게 |
Methods of Making Chimeric Antigen Receptor-Expressing Cells
|
CN115397460A
(en)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
Methods of making cells expressing chimeric antigen receptors
|
CN111269326A
(en)
*
|
2020-02-28 |
2020-06-12 |
南京北恒生物科技有限公司 |
Novel chimeric antigen receptor and use thereof
|
BR112022017727A2
(en)
|
2020-03-03 |
2022-11-16 |
Pic Therapeutics Inc |
EIF4E INHIBITORS AND USES THEREOF
|
AU2021357520A1
(en)
|
2020-03-05 |
2022-09-29 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
JP2023517063A
(en)
|
2020-03-10 |
2023-04-21 |
マサチューセッツ インスティテュート オブ テクノロジー |
Methods and compositions for generating engineered memory-like NK cells
|
CN115485295A
(en)
|
2020-03-10 |
2022-12-16 |
麻省理工学院 |
Compositions and methods for immunotherapy of NPM1 c-positive cancers
|
CN113402612A
(en)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技(香港)有限公司 |
Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
|
IL296451A
(en)
|
2020-03-19 |
2022-11-01 |
Kymera Therapeutics Inc |
Mdm2 degraders and uses thereof
|
EP4127144A1
(en)
|
2020-03-31 |
2023-02-08 |
Sana Biotechnology, Inc. |
Targeted lipid particles and compositions and uses thereof
|
EP3892720A1
(en)
|
2020-04-06 |
2021-10-13 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Presenting cell and use thereof in cell therapy
|
US20230149462A1
(en)
|
2020-04-10 |
2023-05-18 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
WO2021211663A1
(en)
*
|
2020-04-14 |
2021-10-21 |
St. Jude Children's Research Hospital, Inc. |
Chimeric myd88 receptors
|
US20210324331A1
(en)
*
|
2020-04-15 |
2021-10-21 |
Amgen Inc. |
Process for generating genetically engineered autologous t cells
|
GB202005599D0
(en)
|
2020-04-17 |
2020-06-03 |
Univ London |
Modulation of t cell cytotoxicity and related therapy
|
EP4142746A1
(en)
|
2020-04-28 |
2023-03-08 |
Achilles Therapeutics UK Limited |
T cell therapy
|
GB202006254D0
(en)
|
2020-04-28 |
2020-06-10 |
Institute Of Cancer Res |
Anti-cancer vaccines and related therapy
|
AU2021263765A1
(en)
|
2020-04-28 |
2022-12-01 |
Juno Therapeutics, Inc. |
Combination of BCMA-directed T cell therapy and an immunomodulatory compound
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
CN115698009A
(en)
|
2020-05-01 |
2023-02-03 |
吉利德科学公司 |
CD73 inhibiting 2,4-dioxopyrimidine compounds
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
CN115485303A
(en)
|
2020-05-05 |
2022-12-16 |
瑞泽恩制药公司 |
CAR COMPRISING CD28 zeta AND CD3 zeta
|
WO2021228999A1
(en)
|
2020-05-12 |
2021-11-18 |
Institut Curie |
Neoantigenic epitopes associated with sf3b1 mutations
|
JP2023528215A
(en)
|
2020-05-13 |
2023-07-04 |
ジュノー セラピューティクス インコーポレイテッド |
Methods of identifying features associated with clinical response and uses thereof
|
EP4150057A2
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
US20230190780A1
(en)
*
|
2020-05-15 |
2023-06-22 |
Precision Biosciences, Inc. |
Methods for immunotherapy
|
WO2021237068A2
(en)
|
2020-05-21 |
2021-11-25 |
Board Of Regents, The University Of Texas System |
T cell receptors with vgll1 specificity and uses thereof
|
IL298558A
(en)
|
2020-05-27 |
2023-01-01 |
Antion Biosciences Sa |
Adapter molecules to re-direct car t cells to an antigen of interest
|
US12043654B2
(en)
|
2020-06-02 |
2024-07-23 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Anti-GCC antibody and CAR thereof for treating digestive system cancer
|
TW202210483A
(en)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Crystalline forms of irak degraders
|
EP4161536A1
(en)
|
2020-06-04 |
2023-04-12 |
Carisma Therapeutics Inc. |
Novel constructs for chimeric antigen receptors
|
WO2021244654A1
(en)
*
|
2020-06-05 |
2021-12-09 |
Nanjing Legend Biotech Co., Ltd. |
Activation induced cytokine production in immune cells
|
MX2022015611A
(en)
|
2020-06-08 |
2023-04-18 |
Janssen Biotech Inc |
Cell-based assay for determining the in vitro tumor killing activity of chimeric antigen expressing immune cells.
|
WO2021252920A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
MX2022015852A
(en)
|
2020-06-23 |
2023-01-24 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6- dione derivatives.
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
US20240216508A1
(en)
|
2020-06-26 |
2024-07-04 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
CN116490518A
(en)
|
2020-07-17 |
2023-07-25 |
西穆尔克斯股份有限公司 |
Chimeric MyD88 receptor for redirecting immunosuppressive signaling and related compositions and methods
|
KR102297396B1
(en)
|
2020-07-29 |
2021-09-06 |
(주)티카로스 |
Immune Synapse-Stabilizing Chimeric Antigen Receptor(CAR) T Cell
|
US20230303974A1
(en)
|
2020-07-30 |
2023-09-28 |
Institut Curie |
Immune Cells Defective for SOCS1
|
US11578102B2
(en)
|
2020-07-31 |
2023-02-14 |
Leidos, Inc. |
LAG3 binding peptides
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
WO2022029660A1
(en)
|
2020-08-05 |
2022-02-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
US20230293581A1
(en)
|
2020-08-13 |
2023-09-21 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
US20230302134A1
(en)
|
2020-08-13 |
2023-09-28 |
Yale University |
Compositions and methods for engineering and selection of car t cells with desired phenotypes
|
WO2022036041A1
(en)
|
2020-08-14 |
2022-02-17 |
Kite Pharma, Inc |
Improving immune cell function
|
US20240240255A1
(en)
|
2020-08-17 |
2024-07-18 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
IL300497A
(en)
|
2020-08-20 |
2023-04-01 |
A2 Biotherapeutics Inc |
Compositions and methods for treating ceacam positive cancers
|
MX2023002041A
(en)
|
2020-08-20 |
2023-04-27 |
A2 Biotherapeutics Inc |
Compositions and methods for treating mesothelin positive cancers.
|
IL300489A
(en)
|
2020-08-21 |
2023-04-01 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
US20220064596A1
(en)
|
2020-08-25 |
2022-03-03 |
Kite Pharma, Inc. |
T cells with improved functionality
|
US20230302135A1
(en)
*
|
2020-08-26 |
2023-09-28 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Hybrid allosteric receptor-engineered stem cells
|
JP2023548662A
(en)
|
2020-10-12 |
2023-11-20 |
レイドス, インコーポレイテッド |
immunomodulatory peptides
|
JP2023545472A
(en)
*
|
2020-10-16 |
2023-10-30 |
ネオンク テクノロジーズ インク. |
Combination of POH and remdesivir for the treatment of CNS infections
|
EP4232071A1
(en)
|
2020-10-23 |
2023-08-30 |
Asher Biotherapeutics, Inc. |
Fusions with cd8 antigen binding molecules for modulating immune cell function
|
AU2021369507A1
(en)
|
2020-10-28 |
2023-06-01 |
Kite Pharma, Inc. |
Flow cytometric method for characterization of t-cell impurities
|
CA3199839A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
WO2022104109A1
(en)
|
2020-11-13 |
2022-05-19 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
JP2023549504A
(en)
|
2020-11-13 |
2023-11-27 |
ノバルティス アーゲー |
Combination therapy with chimeric antigen receptor (CAR) expressing cells
|
CN112195250A
(en)
*
|
2020-11-20 |
2021-01-08 |
山东省医学科学院附属医院 |
qPCR kit and application
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
WO2022133169A1
(en)
|
2020-12-18 |
2022-06-23 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
EP4267623A1
(en)
|
2020-12-24 |
2023-11-01 |
Kite Pharma, Inc. |
Prostate cancer chimeric antigen receptors
|
CN117396607A
(en)
|
2020-12-30 |
2024-01-12 |
阿劳诺斯治疗公司 |
Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
|
WO2022146891A2
(en)
|
2020-12-31 |
2022-07-07 |
Sana Biotechnology, Inc. |
Methods and compositions for modulating car-t activity
|
AU2022205653A1
(en)
|
2021-01-10 |
2023-07-27 |
Kite Pharma, Inc. |
T cell therapy
|
AU2022206324A1
(en)
|
2021-01-11 |
2023-07-20 |
Sana Biotechnology, Inc. |
Use of cd8-targeted viral vectors
|
EP4274597A1
(en)
|
2021-01-11 |
2023-11-15 |
BicycleTX Limited |
Methods for treating cancer
|
JP2024505428A
(en)
|
2021-01-14 |
2024-02-06 |
アンスティテュ キュリー |
HER2 single domain antibody variants and their CARs
|
UY39610A
(en)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
ANTI-EGFR ANTIBODY-DRUG CONJUGATES
|
US20240115607A1
(en)
|
2021-01-26 |
2024-04-11 |
Cytocares (Shanghai) Inc. |
Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
|
JP2024505184A
(en)
*
|
2021-01-27 |
2024-02-05 |
エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド |
Bispecific CAR T cells for B-cell malignancies
|
EP4284512A1
(en)
|
2021-01-28 |
2023-12-06 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for treating cytokine release syndrome
|
IL303847A
(en)
|
2021-01-28 |
2023-08-01 |
Allogene Therapeutics Inc |
Methods for transducing immune cells
|
EP4288430A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
CN116867494A
(en)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
IRAK4 degrading agent and use thereof
|
EP4294950A1
(en)
|
2021-02-20 |
2023-12-27 |
Kite Pharma, Inc. |
Gene markers for selecting immunotherapies
|
CN117693508A
(en)
|
2021-03-03 |
2024-03-12 |
朱诺治疗学股份有限公司 |
Combination of T cell therapy and DGK inhibitors
|
CA3212530A1
(en)
|
2021-03-05 |
2022-09-09 |
Shanghai GenBase Biotechnology Co., Ltd. |
Anti-cldn6 antibody and use thereof
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
WO2022189626A2
(en)
|
2021-03-11 |
2022-09-15 |
Mnemo Therapeutics |
Tumor neoantigenic peptides
|
EP4304634A1
(en)
|
2021-03-11 |
2024-01-17 |
Institut Curie |
Transmembrane neoantigenic peptides
|
IL305809A
(en)
|
2021-03-11 |
2023-11-01 |
Mnemo Therapeutics |
Tumor neoantigenic peptides and uses thereof
|
AU2022234333A1
(en)
|
2021-03-11 |
2023-09-28 |
Kite Pharma, Inc. |
Improving immune cell function
|
JPWO2022196719A1
(en)
|
2021-03-17 |
2022-09-22 |
|
|
CA3210581A1
(en)
|
2021-03-22 |
2022-09-29 |
Neil HAIG |
Methods of determining potency of a therapeutic cell composition
|
CA3208944A1
(en)
|
2021-03-22 |
2022-09-29 |
Edith NALBANDIAN |
Method to assess potency of viral vector particles
|
BR112023019847A2
(en)
|
2021-03-29 |
2023-11-07 |
Juno Therapeutics Inc |
METHODS FOR DOSING AND TREATMENT WITH A COMBINATION OF A CHECKPOINT INHIBITOR THERAPY AND A CAR T CELL THERAPY
|
AU2022252220A1
(en)
|
2021-03-29 |
2023-10-12 |
Juno Therapeutics, Inc. |
Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
|
TW202304979A
(en)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
|
EP4320435A1
(en)
|
2021-04-09 |
2024-02-14 |
Achilles Therapeutics UK Limited |
Batch release assay for pharmaceutical products relating to t cell therapies
|
GB202109886D0
(en)
|
2021-07-08 |
2021-08-25 |
Achilles Therapeutics Uk Ltd |
Assay
|
TW202302145A
(en)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
|
EP4323943A1
(en)
|
2021-04-16 |
2024-02-21 |
Kite Pharma, Inc. |
Methods and systems for scheduling a patient-specific immunotherapy procedure
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
IL307612A
(en)
|
2021-04-16 |
2023-12-01 |
Celgene Corp |
Combination therapies with bcma-directed t cell therapy
|
US20220354892A1
(en)
|
2021-04-16 |
2022-11-10 |
Kite Pharma, Inc. |
Taci binding molecules
|
CA3214280A1
(en)
|
2021-04-16 |
2022-10-20 |
Julie Ann RYTLEWSKI |
T cell therapy in patients who have had prior stem cell transplant
|
AU2022261141A1
(en)
*
|
2021-04-23 |
2023-11-30 |
Myeloid Therapeutics, Inc. |
Compositions and methods for conditioning patients for cell therapy
|
US20240216426A1
(en)
|
2021-04-27 |
2024-07-04 |
Takeda Pharmaceutical Company Limited |
Recombinant antigen presenting cells
|
EP4330381A1
(en)
|
2021-04-27 |
2024-03-06 |
Novartis AG |
Viral vector production system
|
IL308231A
(en)
|
2021-05-04 |
2024-01-01 |
Regeneron Pharma |
Chimeric antigen receptors with mage-a4 specificity and uses thereof
|
CN117916256A
(en)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
Methods for stimulating and transducing T cells
|
WO2022241151A2
(en)
|
2021-05-14 |
2022-11-17 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
WO2022246293A1
(en)
|
2021-05-19 |
2022-11-24 |
Sana Biotechnology, Inc. |
Hypoimmunogenic rhd negative primary t cells
|
CA3221231A1
(en)
|
2021-05-24 |
2022-12-01 |
Kite Pharma, Inc. |
Chimeric antigen receptor
|
AU2022280871A1
(en)
*
|
2021-05-26 |
2023-12-07 |
Emory University |
Jak inhibitors for managing conditions in patients with down's syndrome or other trisomy
|
CA3216346A1
(en)
|
2021-05-27 |
2022-12-01 |
Edward Rebar |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
WO2022251712A1
(en)
|
2021-05-28 |
2022-12-01 |
Sana Biotechnology, Inc. |
Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
|
WO2022256448A2
(en)
|
2021-06-01 |
2022-12-08 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing, or modifying genes
|
BR112023022097A2
(en)
|
2021-06-07 |
2023-12-19 |
Agonox Inc |
CXCR5, PD-1 AND ICOS EXPRESSING TUMOR-REACTIVE CD4 T CELLS AND THEIR USE
|
KR20240019811A
(en)
|
2021-06-08 |
2024-02-14 |
카이트 파마 인코포레이티드 |
GPC3 binding molecule
|
EP4370676A2
(en)
|
2021-06-18 |
2024-05-22 |
Artisan Development Labs, Inc. |
Compositions and methods for targeting, editing or modifying human genes
|
CN117580946A
(en)
|
2021-06-22 |
2024-02-20 |
阿基里斯治疗英国有限公司 |
Method for producing antigen-specific T cells
|
CA3222439A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2022271684A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
AU2022297367A1
(en)
|
2021-06-23 |
2023-12-07 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
EP4363059A1
(en)
|
2021-06-29 |
2024-05-08 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
US20230027004A1
(en)
|
2021-07-01 |
2023-01-26 |
Kite Pharma, Inc. |
Closed-system and method for autologous and allogeneic cell therapy manufacturing
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
CN117597738A
(en)
|
2021-07-02 |
2024-02-23 |
凯德药业股份有限公司 |
Method for identifying variants in gene products from gene constructs for cell therapy applications
|
WO2023281097A1
(en)
|
2021-07-09 |
2023-01-12 |
Immunic Ag |
Methods for treating cancer
|
EP4370544A2
(en)
|
2021-07-14 |
2024-05-22 |
Sana Biotechnology, Inc. |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
AU2022312508A1
(en)
*
|
2021-07-16 |
2024-01-25 |
Sana Biotechnology, Inc. |
Polycistronic vectors for cell-based therapies
|
WO2023004300A2
(en)
*
|
2021-07-19 |
2023-01-26 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor (car)-t signaling optimization for tuning antigen activation threshold
|
US20230190799A1
(en)
*
|
2021-07-21 |
2023-06-22 |
City Of Hope |
Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
|
IL309500A
(en)
|
2021-07-30 |
2024-02-01 |
Kite Pharma Inc |
Monitoring and management of cell therapy-induced toxicities
|
TW202321457A
(en)
|
2021-08-04 |
2023-06-01 |
美商薩那生物科技公司 |
Use of cd4-targeted viral vectors
|
WO2023014922A1
(en)
|
2021-08-04 |
2023-02-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Lat activating chimeric antigen receptor t cells and methods of use thereof
|
EP4384621A1
(en)
*
|
2021-08-09 |
2024-06-19 |
The Trustees of The University of Pennsylvania |
Optimizing t cell differentiation state with micrornas
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
WO2023019226A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
EP4384193A2
(en)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
KR20240053673A
(en)
|
2021-08-11 |
2024-04-24 |
사나 바이오테크놀로지, 인크. |
Inducible system for altering gene expression in hypoimmunogenic cells
|
KR20240073006A
(en)
|
2021-08-11 |
2024-05-24 |
사나 바이오테크놀로지, 인크. |
Genetically modified primary cells for allogeneic cell therapy
|
WO2023021113A1
(en)
|
2021-08-18 |
2023-02-23 |
Julius-Maximilians-Universität Würzburg |
Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
|
AR126838A1
(en)
|
2021-08-20 |
2023-11-22 |
Novartis Ag |
METHODS FOR PREPARING CELLS THAT EXPRESS CHIMERIC ANTIGEN RECEPTORS
|
KR20240049813A
(en)
|
2021-08-24 |
2024-04-17 |
에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) |
IL-10 Expressing Cells for Improved Cancer Immunotherapy
|
EP4392421A1
(en)
|
2021-08-25 |
2024-07-03 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
EP4392422A1
(en)
|
2021-08-25 |
2024-07-03 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
IL311712A
(en)
|
2021-09-27 |
2024-05-01 |
Sotio Biotech Inc |
Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
|
KR20240099259A
(en)
|
2021-10-14 |
2024-06-28 |
아스널 바이오사이언시스, 인크. |
Immune cells with co-expressed SHRNA and logic gate system
|
CA3232254A1
(en)
|
2021-10-18 |
2023-04-27 |
Kite Pharma, Inc. |
Signaling domains for chimeric antigen receptors
|
AU2022375782A1
(en)
|
2021-10-28 |
2024-05-02 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
CN118201941A
(en)
|
2021-10-29 |
2024-06-14 |
吉利德科学公司 |
CD73 compounds
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
IL312540A
(en)
|
2021-11-16 |
2024-07-01 |
Sotio Biotech Inc |
Treatment of myxoid/round cell liposarcoma patients
|
WO2023092119A2
(en)
|
2021-11-22 |
2023-05-25 |
Ludwig Institute For Cancer Research Ltd |
Methods for predicting responsiveness to a cancer therapy
|
WO2023105000A1
(en)
|
2021-12-09 |
2023-06-15 |
Zygosity Limited |
Vector
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
TW202342498A
(en)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
Modified paramyxoviridae fusion glycoproteins
|
CA3237577A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
US20240124412A1
(en)
|
2021-12-22 |
2024-04-18 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023122337A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
WO2023126458A1
(en)
|
2021-12-28 |
2023-07-06 |
Mnemo Therapeutics |
Immune cells with inactivated suv39h1 and modified tcr
|
WO2023129929A1
(en)
|
2021-12-30 |
2023-07-06 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
US20230227779A1
(en)
|
2022-01-19 |
2023-07-20 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment
|
WO2023139269A1
(en)
|
2022-01-21 |
2023-07-27 |
Mnemo Therapeutics |
Modulation of suv39h1 expression by rnas
|
TW202340168A
(en)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7 inhibitors
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023154890A2
(en)
*
|
2022-02-11 |
2023-08-17 |
Fred Hutchinson Cancer Center |
Chimeric antigen receptors binding steap1
|
WO2023154578A1
(en)
|
2022-02-14 |
2023-08-17 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
WO2023159001A1
(en)
|
2022-02-15 |
2023-08-24 |
Kite Pharma, Inc. |
Predicting adverse events from immunotherapy
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023164440A1
(en)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
|
TW202340457A
(en)
|
2022-02-28 |
2023-10-16 |
美商凱特製藥公司 |
Allogeneic therapeutic cells
|
WO2023167882A1
(en)
|
2022-03-01 |
2023-09-07 |
Artisan Development Labs, Inc. |
Composition and methods for transgene insertion
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
WO2023170606A1
(en)
|
2022-03-08 |
2023-09-14 |
Alentis Therapeutics Ag |
Use of anti-claudin-1 antibodies to increase t cell availability
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173137A1
(en)
|
2022-03-11 |
2023-09-14 |
Yale University |
Compositions and methods for efficient and stable genetic modification of eukaryotic cells
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
WO2023178348A1
(en)
|
2022-03-18 |
2023-09-21 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetically engineered t-cell co-receptors and methods of use thereof
|
WO2023180552A1
(en)
|
2022-03-24 |
2023-09-28 |
Institut Curie |
Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
|
US20230355796A1
(en)
|
2022-03-24 |
2023-11-09 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
GB202204386D0
(en)
|
2022-03-28 |
2022-05-11 |
Cambridge Entpr Ltd |
Engineered immune cell platform
|
WO2023193015A1
(en)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
TW202345901A
(en)
|
2022-04-05 |
2023-12-01 |
美商基利科學股份有限公司 |
Combination therapy for treating colorectal cancer
|
WO2023196921A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Granzyme expressing t cells and methods of use
|
WO2023196933A1
(en)
|
2022-04-06 |
2023-10-12 |
The Regents Of The University Of Colorado, A Body Corporate |
Chimeric antigen receptor t cells and methods of use thereof
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023211972A1
(en)
|
2022-04-28 |
2023-11-02 |
Medical University Of South Carolina |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023220644A1
(en)
|
2022-05-10 |
2023-11-16 |
Yale University |
Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023220641A2
(en)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Methods and uses related to t cell therapy and production of same
|
EP4279085A1
(en)
|
2022-05-20 |
2023-11-22 |
Mnemo Therapeutics |
Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
|
WO2023230581A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
US11878958B2
(en)
|
2022-05-25 |
2024-01-23 |
Ikena Oncology, Inc. |
MEK inhibitors and uses thereof
|
WO2023230272A1
(en)
|
2022-05-27 |
2023-11-30 |
Kite Pharma, Inc. |
Non-viral delivery of cell therapy constructs
|
US20230392119A1
(en)
|
2022-05-27 |
2023-12-07 |
Kite Pharma, Inc. |
Compositions and methods for preparing engineered lymphocytes for cell therapy
|
WO2023240143A1
(en)
|
2022-06-09 |
2023-12-14 |
Kite Pharma, Inc. |
Methods of preparing lymphocytes for cell therapy cross reference to related applications
|
WO2023239940A1
(en)
|
2022-06-10 |
2023-12-14 |
Research Development Foundation |
Engineered fcriib selective igg1 fc variants and uses thereof
|
WO2023242343A1
(en)
|
2022-06-15 |
2023-12-21 |
Immunoscape Pte. Ltd. |
Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024006929A1
(en)
|
2022-07-01 |
2024-01-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
WO2024033879A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Hypoimmunogenic modified cells
|
WO2024040208A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
|
WO2024040207A1
(en)
|
2022-08-19 |
2024-02-22 |
Sotio Biotech Inc. |
Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
WO2024044670A1
(en)
|
2022-08-26 |
2024-02-29 |
Kite Pharma, Inc. |
Improving immune cell function
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024056809A1
(en)
|
2022-09-15 |
2024-03-21 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
WO2024064824A2
(en)
|
2022-09-21 |
2024-03-28 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
|
WO2024062138A1
(en)
|
2022-09-23 |
2024-03-28 |
Mnemo Therapeutics |
Immune cells comprising a modified suv39h1 gene
|
WO2024073583A1
(en)
|
2022-09-30 |
2024-04-04 |
Caribou Biosciences, Inc. |
Anti-ror1 chimeric antigen receptors (cars), car-nk cells and related methods
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
US20240165160A1
(en)
|
2022-10-28 |
2024-05-23 |
Kite Pharma, Inc. |
Efficacy and durable response of immunotherapy
|
US20240158869A1
(en)
|
2022-10-28 |
2024-05-16 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy
|
US20240148790A1
(en)
|
2022-10-28 |
2024-05-09 |
Kite Pharma, Inc. |
Expedited administration of engineered lymphocytes
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
WO2024097311A2
(en)
|
2022-11-02 |
2024-05-10 |
Sana Biotechnology, Inc. |
Hypoimmunogenic mail cells, methods of making and methods of using same
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
WO2024107646A1
(en)
|
2022-11-14 |
2024-05-23 |
Caribou Biosciences, Inc. |
Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
|
WO2024112894A1
(en)
|
2022-11-22 |
2024-05-30 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2024118593A1
(en)
|
2022-11-28 |
2024-06-06 |
Allogene Therapeutics Inc. |
Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
|
WO2024119074A1
(en)
|
2022-12-01 |
2024-06-06 |
Generation Bio Co. |
Stealth lipid nanoparticle compositions for cell targeting
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
WO2024124132A1
(en)
|
2022-12-09 |
2024-06-13 |
Juno Therapeutics, Inc. |
Machine learning methods for predicting cell phenotype using holographic imaging
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
WO2024137852A1
(en)
|
2022-12-22 |
2024-06-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|